The	O
actions	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
suggest	O
a	O
novel	O
step	O
in	O
the	O
activation	O
of	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Cyclosporin	O
A	O
and	O
FK506	O
are	O
immunosuppressive	O
compounds	O
that	O
have	O
similar	O
inhibitory	O
effects	O
on	O
the	O
expression	O
of	O
several	O
lymphokines	B-protein
produced	O
by	O
T	B-cell_type
lymphocytes	I-cell_type
.	O

Despite	O
their	O
similar	O
effects	O
the	O
drugs	O
bind	O
to	O
two	O
different	O
cytosolic	B-protein
protein	I-protein
,	O
cyclophilin	B-protein
and	O
FKBP	B-protein
respectively	O
,	O
which	O
raises	O
the	O
possibility	O
that	O
they	O
have	O
different	O
modes	O
of	O
action	O
.	O

Using	O
constructs	O
in	O
which	O
mRNA	B-RNA
production	O
controlled	O
by	O
a	O
specific	O
transcription	B-protein
factor	I-protein
could	O
be	O
readily	O
measured	O
we	O
found	O
that	O
both	O
cyclosporin	O
A	O
and	O
FK506	O
completely	O
inhibited	O
transcription	O
activated	O
by	O
NF-AT	B-protein
,	O
NFIL2	B-protein
A	I-protein
,	O
NFIL2	B-protein
B	I-protein
and	O
partially	O
inhibited	O
transcription	O
activated	O
by	O
NF	B-protein
kappa	I-protein
B	I-protein
.	O

Cyclosporin	O
A	O
and	O
FK506	O
inhibited	O
only	O
transcriptional	O
activation	O
that	O
was	O
dependent	O
on	O
Ca2+	O
mobilization	O
.	O

However	O
,	O
cyclosporin	O
A	O
and	O
FK506	O
did	O
not	O
inhibit	O
Ca2+	O
mobilization	O
dependent	O
expression	O
of	O
c-fos	B-RNA
mRNA	I-RNA
indicating	O
that	O
only	O
a	O
subset	O
of	O
signalling	O
pathways	O
regulated	O
by	O
Ca2+	O
is	O
sensitive	O
to	O
these	O
drugs	O
.	O

Furthermore	O
,	O
we	O
did	O
not	O
observe	O
any	O
qualitative	O
differences	O
between	O
the	O
effect	O
of	O
cyclosporin	O
A	O
and	O
FK506	O
on	O
six	O
different	O
transcription	B-protein
factors	I-protein
which	O
suggests	O
that	O
these	O
drugs	O
may	O
interfere	O
with	O
the	O
activity	O
of	O
a	O
novel	O
Ca2+	O
dependent	O
step	O
that	O
regulates	O
several	O
transcription	B-protein
factors	I-protein
.	O

The	NULL
EMBO	NULL
Journal	NULL
vol.9	NULL
no	NULL
.	NULL

13	NULL
pp.4425-4433	NULL
,	NULL
1990	NULL
The	NULL
actions	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggest	NULL
a	NULL
novel	NULL
step	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
Petri	NULL
S.Mattila'*	NULL
,	NULL
Katharine	NULL
$	NULL
.Uliman*	NULL
>	NULL
,	NULL
Steven	NULL
Fiering	NULL
'	NULL
,	NULL
Elizabeth	NULL
A.Emmel®	NULL
,	NULL
Michael	NULL
McCutcheon	NULL
``	NULL
,	NULL
Gerald	NULL
R.Crabtree*	NULL
``	NULL
and	NULL
Leonard	NULL
A.Herzenberg	NULL
'	NULL
Departments	NULL
of	NULL
'Genetics	NULL
,	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
*Pathology	NULL
and	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
Stanford	NULL
University	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Stanford	NULL
,	NULL
CA	NULL
94305	NULL
,	NULL
USA	NULL
Present	NULL
address	NULL
:	NULL
Department	NULL
of	NULL
Bacteriology	NULL
and	NULL
Immunology	NULL
,	NULL
University	NULL
of	NULL
Helsinki	NULL
,	NULL
Haartmaninkatu	NULL
3	NULL
,	NULL
Helsinki	NULL
00290	NULL
,	NULL
Finland	NULL
Corresponding	NULL
author	NULL
Communicated	NULL
by	NULL
O.	NULL
Mikela	NULL
Cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
are	NULL
immunosuppressive	NULL
compounds	NULL
that	NULL
have	NULL
similar	NULL
inhibitory	NULL
effects	NULL
on	NULL
the	NULL
expression	NULL
of	NULL
several	NULL
lymphokines	NULL
produced	NULL
by	NULL
T	NULL
lymphocytes	NULL
.	NULL

Despite	NULL
their	NULL
similar	NULL
effects	NULL
the	NULL
drugs	NULL
bind	NULL
to	NULL
two	NULL
different	NULL
cytosolic	NULL
proteins	NULL
,	NULL
cyclophilin	NULL
and	NULL
FKBP	NULL
respectively	NULL
,	NULL
which	NULL
raises	NULL
the	NULL
possibility	NULL
that	NULL
they	NULL
have	NULL
different	NULL
modes	NULL
of	NULL
action	NULL
.	NULL

Using	NULL
constructs	NULL
in	NULL
which	NULL
mRNA	NULL
production	NULL
controlled	NULL
by	NULL
a	NULL
specific	NULL
transcription	NULL
factor	NULL
could	NULL
be	NULL
readily	NULL
measured	NULL
we	NULL
found	NULL
that	NULL
both	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
completely	NULL
inhibited	NULL
transcription	NULL
activated	NULL
by	NULL
NF-AT	NULL
,	NULL
NFIL2	NULL
A	NULL
,	NULL
NFIL2	NULL
B	NULL
and	NULL
partially	NULL
inhibited	NULL
transcription	NULL
activated	NULL
by	NULL
NFxB	NULL
.	NULL

Cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
inhibited	NULL
only	NULL
transcriptional	NULL
activation	NULL
that	NULL
was	NULL
dependent	NULL
on	NULL
Ca**	NULL
mobilization	NULL
.	NULL

However	NULL
,	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
did	NULL
not	NULL
inhibit	NULL
Ca**	NULL
mobilization	NULL
dependent	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
indicating	NULL
that	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
signalling	NULL
pathways	NULL
regulated	NULL
by	NULL
is	NULL
sensitive	NULL
to	NULL
these	NULL
drugs	NULL
.	NULL

Furthermore	NULL
,	NULL
we	NULL
did	NULL
not	NULL
observe	NULL
any	NULL
qualitative	NULL
differences	NULL
between	NULL
the	NULL
effect	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
on	NULL
six	NULL
different	NULL
transcription	NULL
factors	NULL
which	NULL
suggests	NULL
that	NULL
these	NULL
drugs	NULL
may	NULL
interfere	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
novel	NULL
Ca**	NULL
dependent	NULL
step	NULL
that	NULL
regulates	NULL
several	NULL
transcription	NULL
factors	NULL
.	NULL

Key	NULL
words	NULL
:	NULL
cyclosporin	NULL
A/FK506/T	NULL
lymphocyte	NULL
activa-tion/transcription	NULL
Introduction	NULL
Activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
is	NULL
a	NULL
complex	NULL
process	NULL
requiring	NULL
recognition	NULL
of	NULL
antigen	NULL
by	NULL
the	NULL
T	NULL
cell	NULL
antigen	NULL
receptor	NULL
as	NULL
well	NULL
as	NULL
concomitant	NULL
signals	NULL
from	NULL
antigen	NULL
presenting	NULL
cells	NULL
in	NULL
the	NULL
form	NULL
of	NULL
the	NULL
cytokines	NULL
interleukin	NULL
1	NULL
or	NULL
interleukin	NULL
6	NULL
.	NULL

These	NULL
events	NULL
lead	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
second	NULL
messenger	NULL
pathways	NULL
such	NULL
as	NULL
tyrosme	NULL
kinases	NULL
and	NULL
protem	NULL
kinase	NULL
C	NULL
and	NULL
to	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca**	NULL
(	NULL
Weiss	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Wiskocil	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
;	NULL
Mustelin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

These	NULL
events	NULL
on	NULL
the	NULL
cell	NULL
membrane	NULL
initiate	NULL
a	NULL
sequential	NULL
activation	NULL
of	NULL
a	NULL
group	NULL
of	NULL
genes	NULL
that	NULL
in	NULL
turn	NULL
give	NULL
rise	NULL
to	NULL
proliferation	NULL
and	NULL
immunologic	NULL
function	NULL
(	NULL
see	NULL
Crabtree	NULL
,	NULL
1989	NULL
for	NULL
review	NULL
)	NULL
.	NULL

Cyclosporin	NULL
A	NULL
,	NULL
a	NULL
cyclic	NULL
undecapeptide	NULL
,	NULL
inhibits	NULL
T	NULL
cell	NULL
activation	NULL
at	NULL
an	NULL
early	NULL
step	NULL
and	NULL
thereby	NULL
interferes	NULL
with	NULL
numerous	NULL
immunoregulatory	NULL
functions	NULL
carried	NULL
out	NULL
by	NULL
activated	NULL
T	NULL
cells	NULL
through	NULL
©	NULL
Oxford	NULL
University	NULL
Press	NULL
lymphokines	NULL
such	NULL
as	NULL
interleukins	NULL
2	NULL
,	NULL
3	NULL
and	NULL
4	NULL
,	NULL
y	NULL
interferon	NULL
,	NULL
GM-GSF	NULL
and	NULL
TNF	NULL
a	NULL
(	NULL
Elliot	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Bickel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Arai	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Tocci	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Treatment	NULL
with	NULL
cyclosporin	NULL
A	NULL
does	NULL
not	NULL
prevent	NULL
the	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca	NULL
``	NULL
*	NULL
and	NULL
kinase	NULL
activation	NULL
,	NULL
however	NULL
,	NULL
the	NULL
transcriptional	NULL
activation	NULL
of	NULL
certain	NULL
genes	NULL
is	NULL
inhibited	NULL
.	NULL

Recently	NULL
we	NULL
found	NULL
that	NULL
cyclosporin	NULL
A	NULL
,	NULL
at	NULL
concentrations	NULL
with	NULL
no	NULL
detectable	NULL
toxic	NULL
effect	NULL
on	NULL
cells	NULL
,	NULL
inhibits	NULL
the	NULL
activation	NULL
of	NULL
specific	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
genes	NULL
such	NULL
as	NULL
interleukin	NULL
2	NULL
which	NULL
are	NULL
expressed	NULL
early	NULL
in	NULL
T	NULL
lymphocyte	NULL
activation	NULL
(	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

These	NULL
findings	NULL
placed	NULL
the	NULL
action	NULL
of	NULL
cyclosporin	NULL
A	NULL
at	NULL
or	NULL
proximal	NULL
to	NULL
the	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
gene	NULL
activation	NULL
but	NULL
distal	NULL
to	NULL
the	NULL
known	NULL
cytoplasmic	NULL
events	NULL
in	NULL
the	NULL
pathway	NULL
.	NULL

Cyclosporin	NULL
A	NULL
binds	NULL
and	NULL
inhibits	NULL
the	NULL
activity	NULL
of	NULL
cyclophilin	NULL
(	NULL
Haendler	NULL
eral	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
,	NULL
a	NULL
peptidyl-prolyl	NULL
cis-trans	NULL
isomerase	NULL
(	NULL
Fisher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Takahashi	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
that	NULL
may	NULL
play	NULL
a	NULL
role	NULL
in	NULL
the	NULL
folding	NULL
of	NULL
proteins	NULL
in	NULL
vivo	NULL
(	NULL
Lang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

In	NULL
Drosophila	NULL
melanogaster	NULL
a	NULL
gene	NULL
homologous	NULL
to	NULL
cyclophilin	NULL
,	NULL
ninaA4	NULL
,	NULL
affects	NULL
the	NULL
expression	NULL
of	NULL
rhodopsin	NULL
by	NULL
a	NULL
post-translational	NULL
mechanism	NULL
which	NULL
may	NULL
occur	NULL
via	NULL
a	NULL
putative	NULL
isomerase	NULL
activity	NULL
of	NULL
ninad4	NULL
protein	NULL
on	NULL
the	NULL
folding	NULL
of	NULL
rhodopsin	NULL
(	NULL
Schneuwly	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Shieh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

However	NULL
,	NULL
cyclosporin	NULL
A	NULL
may	NULL
mediate	NULL
its	NULL
effect	NULL
by	NULL
a	NULL
mechanism	NULL
that	NULL
is	NULL
not	NULL
directly	NULL
linked	NULL
to	NULL
the	NULL
inhibition	NULL
of	NULL
the	NULL
isomerase	NULL
activity	NULL
of	NULL
cyclophilin	NULL
.	NULL

In	NULL
Newrospora	NULL
crassa	NULL
and	NULL
Saccharomyces	NULL
cerevisiae	NULL
a	NULL
protein	NULL
homologous	NULL
to	NULL
cyclophilin	NULL
mediates	NULL
the	NULL
toxic	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
apparently	NULL
by	NULL
forming	NULL
a	NULL
toxic	NULL
complex	NULL
with	NULL
cyclosporin	NULL
A	NULL
.	NULL

This	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
finding	NULL
that	NULL
in	NULL
N.crassa	NULL
heterokaryons	NULL
having	NULL
one	NULL
mutant	NULL
allele	NULL
of	NULL
cyclophilin	NULL
and	NULL
one	NULL
normal	NULL
allele	NULL
die	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cyclosporin	NULL
A	NULL
(	NULL
Tropschug	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
all	NULL
the	NULL
cyclosporin	NULL
A	NULL
resistant	NULL
mutants	NULL
either	NULL
lack	NULL
cyclophilin	NULL
or	NULL
have	NULL
a	NULL
mutation	NULL
that	NULL
prevents	NULL
binding	NULL
.	NULL

Similar	NULL
inhibitory	NULL
complexes	NULL
of	NULL
cyclophilin	NULL
and	NULL
cyclosporin	NULL
A	NULL
may	NULL
mediate	NULL
the	NULL
effect	NULL
of	NULL
cyclosporin	NULL
A	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
.	NULL

Recently	NULL
another	NULL
potent	NULL
immunosuppressant	NULL
was	NULL
discovered	NULL
,	NULL
FK506	NULL
,	NULL
that	NULL
has	NULL
biologic	NULL
effects	NULL
very	NULL
similar	NULL
to	NULL
cyclosporin	NULL
A	NULL
but	NULL
is	NULL
a	NULL
macrolide	NULL
with	NULL
a	NULL
different	NULL
chemical	NULL
structure	NULL
than	NULL
cyclosporin	NULL
A	NULL
(	NULL
Sawada	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

Remarkably	NULL
,	NULL
FK506	NULL
also	NULL
binds	NULL
to	NULL
a	NULL
peptidyl-prolyl	NULL
cis-trans	NULL
isomerase	NULL
,	NULL
FKBP	NULL
,	NULL
and	NULL
inhibits	NULL
its	NULL
activity	NULL
(	NULL
Harding	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Siekierka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
,	NULL
however	NULL
,	NULL
FKBP	NULL
has	NULL
no	NULL
sequence	NULL
similarity	NULL
to	NULL
cyclophilin	NULL
(	NULL
Maki	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Standaert	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

This	NULL
raises	NULL
the	NULL
possibility	NULL
of	NULL
dissecting	NULL
the	NULL
signalling	NULL
pathways	NULL
leading	NULL
to	NULL
activation	NULL
of	NULL
individual	NULL
transcription	NULL
factors	NULL
by	NULL
virtue	NULL
of	NULL
sensitivity	NULL
to	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
.	NULL

We	NULL
found	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
the	NULL
two	NULL
drugs	NULL
were	NULL
similar	NULL
on	NULL
each	NULL
of	NULL
the	NULL
four	NULL
transcription	NULL
factors	NULL
that	NULL
were	NULL
inhibited	NULL
and	NULL
on	NULL
each	NULL
of	NULL
the	NULL
two	NULL
transcription	NULL
factors	NULL
that	NULL
were	NULL
not	NULL
inhibited	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
distinguishing	NULL
feature	NULL
of	NULL
the	NULL
transcrlptlon	NULL
factors	NULL
affected	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
is	NULL
that	NULL
they	NULL
require	NULL
Ca'*	NULL
mobilization	NULL
for	NULL
their	NULL
activation	NULL
.	NULL

These	NULL
results	NULL
suggest	NULL
that	NULL
4425	NULL
P.Mattila	NULL
et	NULL
al	NULL
.	NULL

IL-2	NULL
gene	NULL
|	NULL
/Nr-at	NULL
GgAggAAAAAcTgTTTcATAcAGAAGGCGT	NULL
The	NULL
NFAT-lacZ	NULL
-/-	NULL
fome	NULL
construct	NULL
3	NULL
x	NULL
NF-AT	NULL
IL-2	NULL
O	NULL
447	NULL
lacZ	NULL
RNA	NULL
probe	NULL
fragments	NULL
protected	NULL
by	NULL
lacZ	NULL
mRNA	NULL
-	NULL
pmmempmmmmmmmmeme	NULL
250	NULL
Dp	NULL
IL-2	NULL
mRNA	NULL
.	NULL

47	NULL
bp	NULL
bo	NULL
\	NULL
;	NULL
_	NULL
STmuLATED	NULL
___	NULL
ZZ	NULL
FK506	NULL
CsA	NULL
10	NULL
1	NULL
0.1	NULL
0.01	NULL
100	NULL
10	NULL
1	NULL
-	NULL
conc	NULL
.	NULL

of	NULL
drug	NULL
~	NULL
ama	NULL
beta-gal	NULL
.	NULL

activity	NULL
4	NULL
b	NULL
<	NULL
|	NULL
lacZ	NULL
mRNA	NULL
d	NULL
#	NULL
#	NULL
Mik	NULL
|	NULL
<	NULL
-	NULL
250	NULL
bp	NULL
IL-2	NULL
mRNA	NULL
<	NULL
=	NULL
47	NULL
bp	NULL
Fig	NULL
.	NULL

1	NULL
.	NULL

(	NULL
a	NULL
)	NULL
The	NULL
map	NULL
of	NULL
the	NULL
5	NULL
'	NULL
region	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
(	NULL
IL-2	NULL
)	NULL
gene	NULL
and	NULL
the	NULL
structure	NULL
of	NULL
the	NULL
NFAT	NULL
construct	NULL
.	NULL

Sites	NULL
which	NULL
bind	NULL
proteins	NULL
believed	NULL
to	NULL
contribute	NULL
to	NULL
transcriptional	NULL
control	NULL
of	NULL
interleukin	NULL
2	NULL
are	NULL
noted	NULL
with	NULL
the	NULL
names	NULL
of	NULL
the	NULL
putative	NULL
binding	NULL
proteins	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
NFAT	NULL
-lacZ	NULL
construct	NULL
contains	NULL
the	NULL
E.coli	NULL
lacZ	NULL
B-galactosidase	NULL
gene	NULL
attached	NULL
to	NULL
position	NULL
+47	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
which	NULL
precedes	NULL
the	NULL
translational	NULL
start	NULL
site	NULL
for	NULL
interleukin	NULL
2	NULL
.	NULL

A	NULL
trimer	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
site	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
of	NULL
interleukin	NULL
2	NULL
)	NULL
is	NULL
ligated	NULL
to	NULL
a	NULL
minimal	NULL
interleukin	NULL
2	NULL
promoter	NULL
at	NULL
-72	NULL
.	NULL

All	NULL
three	NULL
NF-AT	NULL
sites	NULL
are	NULL
oriented	NULL
5'-3	NULL
'	NULL
.	NULL

The	NULL
location	NULL
of	NULL
the	NULL
RNA	NULL
probe	NULL
(	NULL
370	NULL
bp	NULL
)	NULL
relative	NULL
to	NULL
the	NULL
NFAT	NULL
-lacZ	NULL
construct	NULL
is	NULL
presented	NULL
as	NULL
a	NULL
black	NULL
line	NULL
and	NULL
the	NULL
lower	NULL
lines	NULL
present	NULL
fragments	NULL
of	NULL
the	NULL
RNA	NULL
probe	NULL
protected	NULL
by	NULL
lacZ	NULL
RNA	NULL
(	NULL
250	NULL
bp	NULL
)	NULL
and	NULL
interleukin	NULL
2	NULL
RNA	NULL
(	NULL
47	NULL
bp	NULL
)	NULL
.	NULL

Lower	NULL
case	NULL
letters	NULL
indicate	NULL
NF-AT	NULL
contact	NULL
sites	NULL
determined	NULL
by	NULL
a	NULL
methylation	NULL
interference	NULL
assay	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

(	NULL
b	NULL
)	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
inhibit	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-AT	NULL
and	NULL
transcription	NULL
of	NULL
interleukin	NULL
2	NULL
.	NULL

Jurkat	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
NFAT	NULL
construct	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
h	NULL
with	NULL
ionomycin	NULL
(	NULL
2	NULL
M	NULL
)	NULL
and	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
32	NULL
nM	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
FK506	NULL
or	NULL
cyclosporin	NULL
A	NULL
(	NULL
nM	NULL
)	NULL
.	NULL

Transcription	NULL
of	NULL
lacZ	NULL
mRNA	NULL
from	NULL
the	NULL
NFAT	NULL
-lacZ	NULL
construct	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
ribonuclease	NULL
protection	NULL
assay	NULL
using	NULL
the	NULL
RNA	NULL
probe	NULL
described	NULL
in	NULL
(	NULL
a	NULL
)	NULL
.	NULL

Interleukin	NULL
2	NULL
mRNA	NULL
can	NULL
be	NULL
measured	NULL
on	NULL
the	NULL
same	NULL
lane	NULL
of	NULL
the	NULL
gel	NULL
since	NULL
the	NULL
ribonuclease	NULL
protection	NULL
probe	NULL
contains	NULL
47	NULL
bp	NULL
from	NULL
the	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
interleukin	NULL
2	NULL
.	NULL

B-galactosidase	NULL
activity	NULL
is	NULL
presented	NULL
as	NULL
percent	NULL
of	NULL
maximal	NULL
activity	NULL
and	NULL
it	NULL
correlates	NULL
with	NULL
the	NULL
intensities	NULL
of	NULL
the	NULL
protected	NULL
bands	NULL
representing	NULL
lacZ	NULL
mRNA	NULL
.	NULL

NS	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A.	NULL
Molecular	NULL
weight	NULL
markers	NULL
(	NULL
M.W	NULL
.	NULL
)	NULL

are	NULL
MspI	NULL
digested	NULL
pBR322	NULL
DNA	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
.	NULL

cyclophilin	NULL
and	NULL
FKBP	NULL
affect	NULL
a	NULL
common	NULL
signal	NULL
transduction	NULL
pathway	NULL
that	NULL
requires	NULL
an	NULL
increase	NULL
in	NULL
intracellular	NULL
Ca**	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
gene	NULL
regulation	NULL
during	NULL
T	NULL
lymphocyte	NULL
activation	NULL
.	NULL

Results	NULL
Cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
Changes	NULL
in	NULL
gene	NULL
expression	NULL
which	NULL
mediate	NULL
T	NULL
cell	NULL
activation	NULL
are	NULL
related	NULL
to	NULL
induction	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
such	NULL
as	NULL
c-fos	NULL
(	NULL
Reed	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
and	NULL
NFxB	NULL
(	NULL
Leung	NULL
and	NULL
Nabel	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

Activation	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
which	NULL
is	NULL
a	NULL
growth	NULL
factor	NULL
for	NULL
T	NULL
lymphocytes	NULL
requires	NULL
the	NULL
activity	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
as	NULL
illustrated	NULL
in	NULL
Figure	NULL
la	NULL
(	NULL
Shaw	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
;	NULL
Serfling	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

To	NULL
study	NULL
the	NULL
influence	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
individual	NULL
transcription	NULL
factors	NULL
induced	NULL
during	NULL
T	NULL
lymphocyte	NULL
activation	NULL
the	NULL
human	NULL
leukemic	NULL
cell	NULL
line	NULL
Jurkat	NULL
was	NULL
stably	NULL
transfected	NULL
with	NULL
plasmids	NULL
that	NULL
have	NULL
multiple	NULL
copies	NULL
of	NULL
specific	NULL
binding	NULL
sites	NULL
for	NULL
transcription	NULL
factors	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
Escherichia	NULL
coli	NULL
lacZ	NULL
B-galactosidase	NULL
gene	NULL
.	NULL

We	NULL
chose	NULL
to	NULL
analyze	NULL
the	NULL
transcription	NULL
factor	NULL
binding	NULL
sites	NULL
NFIL2A	NULL
,	NULL
NFIL2B	NULL
and	NULL
NF-AT	NULL
from	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
.	NULL

Although	NULL
interleukin	NULL
2	NULL
gene	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
contain	NULL
NFxB	NULL
and	NULL
AP-1	NULL
binding	NULL
sites	NULL
these	NULL
binding	NULL
sites	NULL
may	NULL
also	NULL
be	NULL
occupied	NULL
by	NULL
other	NULL
transcription	NULL
factors	NULL
and	NULL
therefore	NULL
we	NULL
chose	NULL
to	NULL
analyze	NULL
the	NULL
NFxB	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
immunoglobulin	NULL
x	NULL
4426	NULL
light	NULL
chain	NULL
and	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
metallothionein	NULL
gene	NULL
which	NULL
are	NULL
more	NULL
thoroughly	NULL
characterized	NULL
.	NULL

The	NULL
interleukin	NULL
2	NULL
minimal	NULL
promoter	NULL
was	NULL
used	NULL
in	NULL
most	NULL
of	NULL
the	NULL
constructs	NULL
since	NULL
it	NULL
has	NULL
very	NULL
low	NULL
activity	NULL
by	NULL
itself	NULL
but	NULL
still	NULL
gives	NULL
high	NULL
expression	NULL
when	NULL
linked	NULL
to	NULL
enhancer	NULL
elements	NULL
(	NULL
Verweij	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
construct	NULL
was	NULL
ligated	NULL
to	NULL
SV40	NULL
minimal	NULL
promoter	NULL
which	NULL
contains	NULL
six	NULL
SP-1	NULL
sites	NULL
and	NULL
it	NULL
therefore	NULL
presents	NULL
transcription	NULL
controlled	NULL
by	NULL
both	NULL
AP-1	NULL
and	NULL
SP-1	NULL
binding	NULL
factors	NULL
.	NULL

The	NULL
NFIL2A	NULL
construct	NULL
contained	NULL
the	NULL
TATA	NULL
box	NULL
from	NULL
the	NULL
y	NULL
fibrinogen	NULL
promoter	NULL
but	NULL
very	NULL
similar	NULL
results	NULL
can	NULL
be	NULL
obtained	NULL
with	NULL
a	NULL
construct	NULL
that	NULL
has	NULL
NFIL2ZA	NULL
binding	NULL
sites	NULL
linked	NULL
to	NULL
interleukin	NULL
2	NULL
minimal	NULL
promoter	NULL
(	NULL
unpublished	NULL
observations	NULL
)	NULL
.	NULL

Three	NULL
copies	NULL
of	NULL
each	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
a	NULL
promoter	NULL
construct	NULL
were	NULL
used	NULL
except	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NFIL2ZA	NULL
and	NULL
NFIL2B	NULL
constructs	NULL
where	NULL
four	NULL
copies	NULL
were	NULL
used	NULL
because	NULL
they	NULL
gave	NULL
a	NULL
higher	NULL
level	NULL
of	NULL
expression	NULL
.	NULL

The	NULL
transfected	NULL
plasmids	NULL
contain	NULL
a	NULL
hygromycin	NULL
resistance	NULL
gene	NULL
and	NULL
stable	NULL
transfectants	NULL
were	NULL
selected	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
hygromycin	NULL
.	NULL

Hygromycin	NULL
resistant	NULL
clones	NULL
that	NULL
had	NULL
little	NULL
or	NULL
no	NULL
constitutive	NULL
expression	NULL
but	NULL
expressed	NULL
high	NULL
levels	NULL
of	NULL
-galactosidase	NULL
upon	NULL
stimulation	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
calcium	NULL
ionophore	NULL
were	NULL
selected	NULL
and	NULL
cloned	NULL
with	NULL
the	NULL
fluorescence	NULL
activated	NULL
cell	NULL
sorter	NULL
(	NULL
FACS	NULL
)	NULL
using	NULL
the	NULL
fluorogenic	NULL
substrate	NULL
for	NULL
B-galactosidase	NULL
,	NULL
fluorescein-digalactoside	NULL
(	NULL
Nolan	NULL
ert	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

NF-AT	NULL
directed	NULL
transcription	NULL
was	NULL
assayed	NULL
in	NULL
a	NULL
clone	NULL
of	NULL
Jurkat	NULL
cells	NULL
having	NULL
one	NULL
copy	NULL
of	NULL
a	NULL
construct	NULL
with	NULL
three	NULL
NFAT	NULL
binding	NULL
sites	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
the	NULL
lacZ	NULL
gene	NULL
(	NULL
Figure	NULL
la	NULL
)	NULL
.	NULL

lacZ	NULL
RNA	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
was	NULL
detected	NULL
only	NULL
after	NULL
stimulation	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
.	NULL

This	NULL
inducible	NULL
expression	NULL
of	NULL
lacZ	NULL
mRNA	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
dose	NULL
dependent	NULL
manner	NULL
by	NULL
both	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK	NULL
506	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
RNA	NULL
probe	NULL
fragment	NULL
protected	NULL
by	NULL
lacZ	NULL
mRNA	NULL
in	NULL
the	NULL
ribonuclease	NULL
protection	NULL
assay	NULL
indicated	NULL
that	NULL
the	NULL
NF-AT	NULL
binding	NULL
sites	NULL
ligated	NULL
to	NULL
promoter	NULL
sequences	NULL
from	NULL
interleukin	NULL
2	NULL
(	NULL
-72	NULL
to	NULL
+47	NULL
)	NULL
directed	NULL
correctly	NULL
initiated	NULL
transcripts	NULL
at	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
initiation	NULL
site	NULL
(	NULL
Figure	NULL
la	NULL
)	NULL
.	NULL

Interleukin	NULL
2	NULL
mRNA	NULL
can	NULL
be	NULL
measured	NULL
in	NULL
the	NULL
same	NULL
lane	NULL
of	NULL
the	NULL
gel	NULL
since	NULL
the	NULL
ribonuclease	NULL
protection	NULL
probe	NULL
contains	NULL
47	NULL
bp	NULL
from	NULL
the	NULL
5	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
interleukin	NULL
2	NULL
(	NULL
Figure	NULL
la	NULL
and	NULL
b	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
since	NULL
the	NULL
ribonuclease	NULL
probe	NULL
used	NULL
to	NULL
measure	NULL
interleukin	NULL
2	NULL
and	NULL
lacZ	NULL
transcripts	NULL
is	NULL
identical	NULL
,	NULL
direct	NULL
comparisons	NULL
can	NULL
be	NULL
made	NULL
between	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
transfected	NULL
gene	NULL
and	NULL
the	NULL
activity	NULL
of	NULL
the	NULL
endogenous	NULL
interleukin	NULL
2	NULL
gene	NULL
.	NULL

The	NULL
intensities	NULL
of	NULL
the	NULL
bands	NULL
representing	NULL
lacZ	NULL
mRNA	NULL
correlate	NULL
well	NULL
with	NULL
the	NULL
measured	NULL
3-galactosidase	NULL
enzymatic	NULL
activities	NULL
(	NULL
Figure	NULL
1b	NULL
)	NULL
.	NULL

Similar	NULL
results	NULL
were	NULL
obtained	NULL
when	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
entire	NULL
interleukin	NULL
2	NULL
enhancer	NULL
was	NULL
investigated	NULL
by	NULL
analysis	NULL
of	NULL
induced	NULL
B-galactosidase	NULL
activity	NULL
encoded	NULL
by	NULL
lacZ	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

Both	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
also	NULL
inhibited	NULL
in	NULL
a	NULL
dose	NULL
dependent	NULL
manner	NULL
the	NULL
ability	NULL
of	NULL
the	NULL
NFILZA	NULL
,	NULL
NFIL2B	NULL
and	NULL
NFxB	NULL
binding	NULL
sites	NULL
to	NULL
active	NULL
transcription	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

The	NULL
transcription	NULL
from	NULL
a	NULL
construct	NULL
in	NULL
which	NULL
sites	NULL
for	NULL
both	NULL
AP-1	NULL
and	NULL
SP-1	NULL
are	NULL
controlling	NULL
transcription	NULL
of	NULL
lacZ	NULL
was	NULL
not	NULL
significantly	NULL
affected	NULL
by	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
.	NULL

A	NULL
50	NULL
%	NULL
inhibition	NULL
of	NULL
transcription	NULL
from	NULL
constructs	NULL
sensitive	NULL
to	NULL
these	NULL
drugs	NULL
was	NULL
achieved	NULL
with	NULL
~	NULL
10	NULL
nM	NULL
cyclosporin	NULL
A	NULL
and	NULL
0.1	NULL
nM	NULL
FK506	NULL
(	NULL
Figure	NULL
2	NULL
)	NULL
.	NULL

These	NULL
dose-response	NULL
relationships	NULL
are	NULL
consistent	NULL
with	NULL
previous	NULL
reports	NULL
that	NULL
FK506	NULL
is	NULL
100-fold	NULL
more	NULL
effective	NULL
than	NULL
cyclosporin	NULL
A	NULL
and	NULL
are	NULL
similar	NULL
to	NULL
the	NULL
concentrations	NULL
required	NULL
to	NULL
block	NULL
T	NULL
cell	NULL
activation	NULL
(	NULL
Sawada	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

FK506	NULL
inhibits	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NF-AT	NULL
Electrophoretic	NULL
mobility	NULL
shift	NULL
assays	NULL
were	NULL
performed	NULL
to	NULL
examine	NULL
the	NULL
effect	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
on	NULL
the	NULL
binding	NULL
activity	NULL
of	NULL
NF-AT	NULL
,	NULL
NFIL2B	NULL
and	NULL
AP-1	NULL
transcription	NULL
factors	NULL
(	NULL
Figure	NULL
3	NULL
)	NULL
.	NULL

NF-AT	NULL
binding	NULL
activity	NULL
was	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
as	NULL
demonstrated	NULL
previously	NULL
by	NULL
Emmel	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
and	NULL
it	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
FK506	NULL
(	NULL
Figure	NULL
3a	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
with	NULL
the	NULL
NFIL2B	NULL
binding	NULL
site	NULL
gave	NULL
rise	NULL
to	NULL
an	NULL
inducible	NULL
retarded	NULL
band	NULL
that	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
although	NULL
the	NULL
transcriptional	NULL
activity	NULL
was	NULL
inhibited	NULL
(	NULL
Figure	NULL
3b	NULL
)	NULL
.	NULL

The	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
AP-1	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
FK506	NULL
(	NULL
Figure	NULL
3¢	NULL
)	NULL
.	NULL

Only	NULL
Ca	NULL
``	NULL
*	NULL
regulated	NULL
activities	NULL
are	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
T	NULL
lymphocytes	NULL
require	NULL
the	NULL
concordant	NULL
actions	NULL
of	NULL
two	NULL
signals	NULL
derived	NULL
from	NULL
the	NULL
antigen	NULL
receptor	NULL
and	NULL
interleukin	NULL
1	NULL
or	NULL
interleukin	NULL
6	NULL
for	NULL
activation	NULL
.	NULL

These	NULL
pathways	NULL
can	NULL
to	NULL
some	NULL
extent	NULL
be	NULL
mimicked	NULL
by	NULL
stimulation	NULL
with	NULL
a	NULL
combination	NULL
of	NULL
calcium	NULL
ionophore	NULL
and	NULL
phorbol	NULL
ester	NULL
.	NULL

Transcription	NULL
of	NULL
lacZ	NULL
mRNA	NULL
directed	NULL
by	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NFxB	NULL
site	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
was	NULL
stimulated	NULL
with	NULL
phorbol	NULL
ester	NULL
alone	NULL
and	NULL
this	NULL
phorbol	NULL
ester	NULL
induced	NULL
activity	NULL
was	NULL
completely	NULL
resistant	NULL
to	NULL
FK506	NULL
(	NULL
Figure	NULL
4b	NULL
)	NULL
.	NULL

However	NULL
,	NULL
when	NULL
cells	NULL
were	NULL
stimulated	NULL
with	NULL
phorbol	NULL
ester	NULL
together	NULL
with	NULL
ionomycin	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
was	NULL
further	NULL
enhanced	NULL
4-fold	NULL
.	NULL

The	NULL
increased	NULL
level	NULL
of	NULL
NFxB	NULL
mediated	NULL
transcription	NULL
induced	NULL
by	NULL
calcium	NULL
ionophore	NULL
was	NULL
almost	NULL
completely	NULL
inhibited	NULL
by	NULL
FK506	NULL
Signal	NULL
transduction	NULL
in	NULL
T	NULL
lymphocyte	NULL
activation	NULL
IL2	NULL
NF-AT	NULL
p	NULL
100	NULL
(	NULL
326,447	NULL
)	NULL
|	NULL
3	NULL
O	NULL
g	NULL
50	NULL
|	NULL
FK506	NULL
CsA	NULL
|	NULL
FK506	NULL
CsA	NULL
po	NULL
GC	NULL
a	NULL
0	NULL
y	NULL
NFIL2	NULL
A	NULL
NFIL2	NULL
B	NULL
§	NULL
100	NULL
rj	NULL
&	NULL
8	NULL
5so|	NULL
FKso6	NULL
CsA	NULL
{	NULL
FK506	NULL
CsA	NULL
3	NULL
»	NULL
|	NULL
8	NULL
o	NULL
E	NULL
NF	NULL
kappa	NULL
B|	NULL
CsA	NULL
AP-1+SP1	NULL
©	NULL
100|	NULL
L-	NULL
M	NULL
é	NULL
FK	NULL
506	NULL
CsA	NULL
FK506	NULL
i	NULL
50	NULL
A	NULL
.	NULL

0	NULL
100	NULL
0.001	NULL
0.01	NULL
0.1	NULL
1.0	NULL
10	NULL
0.01	NULL
0.1	NULL
1.0	NULL
10	NULL
100	NULL
0.001	NULL
concentration	NULL
of	NULL
drug	NULL
(	NULL
nM	NULL
)	NULL
Fig	NULL
.	NULL

2	NULL
.	NULL

Dose-response	NULL
to	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
of	NULL
transcription	NULL
mediated	NULL
by	NULL
individual	NULL
transcription	NULL
factors	NULL
.	NULL

Jurkat	NULL
cell	NULL
lines	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
h	NULL
with	NULL
2	NULL
M	NULL
ionomycin	NULL
and	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
.	NULL

Graphs	NULL
in	NULL
different	NULL
boxes	NULL
present	NULL
B-galactosidase	NULL
activities	NULL
of	NULL
different	NULL
clones	NULL
stably	NULL
transfected	NULL
with	NULL
constructs	NULL
containing	NULL
E.coli	NULL
lacZ	NULL
{	NULL
-galactosidase	NULL
gene	NULL
in	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
various	NULL
transcription	NULL
factors	NULL
.	NULL

IL2	NULL
,	NULL
lacZ	NULL
transcription	NULL
controlled	NULL
by	NULL
bases	NULL
-326	NULL
to	NULL
+45	NULL
from	NULL
interleukin	NULL
2	NULL
gene	NULL
(	NULL
proteins	NULL
contributing	NULL
to	NULL
transcription	NULL
from	NULL
this	NULL
region	NULL
are	NULL
described	NULL
in	NULL
Figure	NULL
la	NULL
)	NULL
;	NULL
NF-AT	NULL
,	NULL
lacZ	NULL
transcription	NULL
controlled	NULL
by	NULL
three	NULL
copies	NULL
of	NULL
NF-AT	NULL
binding	NULL
site	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
of	NULL
interleukin	NULL
2	NULL
)	NULL
linked	NULL
to	NULL
-72	NULL
of	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
promoter	NULL
(	NULL
described	NULL
in	NULL
Figure	NULL
la	NULL
)	NULL
;	NULL
NFIL2A	NULL
,	NULL
lacZ	NULL
transcription	NULL
controlled	NULL
by	NULL
four	NULL
copies	NULL
of	NULL
NFIL2A	NULL
binding	NULL
region	NULL
(	NULL
-93	NULL
to	NULL
-65	NULL
of	NULL
interleukin	NULL
2	NULL
)	NULL
linked	NULL
to	NULL
a	NULL
minimal	NULL
y-fibrinogen	NULL
promoter	NULL
;	NULL
NFIL2B	NULL
,	NULL
lacZ	NULL
transcription	NULL
controlled	NULL
by	NULL
four	NULL
copies	NULL
of	NULL
NFIL2B	NULL
binding	NULL
region	NULL
(	NULL
-159	NULL
to	NULL
-134	NULL
of	NULL
interleukin	NULL
2	NULL
)	NULL
linked	NULL
to	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
;	NULL
NFxB	NULL
,	NULL
lacZ	NULL
transcription	NULL
controlled	NULL
by	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NFxB	NULL
site	NULL
of	NULL
the	NULL
mouse	NULL
x	NULL
light	NULL
chain	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
;	NULL
AP-1	NULL
+SP-1	NULL
,	NULL
lacZ	NULL
transcription	NULL
controlled	NULL
by	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
human	NULL
metallothionein	NULL
gene	NULL
linked	NULL
to	NULL
the	NULL
SV40	NULL
promoter	NULL
that	NULL
contains	NULL
six	NULL
SP-1	NULL
sites	NULL
(	NULL
Lee	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

B-galactosidase	NULL
activities	NULL
are	NULL
presented	NULL
as	NULL
percent	NULL
of	NULL
the	NULL
maximal	NULL
activity	NULL
of	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

(	NULL
Figure	NULL
4b	NULL
)	NULL
.	NULL

These	NULL
effects	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
directed	NULL
by	NULL
the	NULL
NFxB	NULL
site	NULL
were	NULL
paralleled	NULL
by	NULL
similar	NULL
changes	NULL
in	NULL
DNA	NULL
binding	NULL
activity	NULL
(	NULL
Figure	NULL
4c	NULL
)	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
cyclosporin	NULL
A	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
was	NULL
similar	NULL
to	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
(	NULL
Figure	NULL
Sa	NULL
)	NULL
.	NULL

The	NULL
sensitivity	NULL
of	NULL
NFxB	NULL
mediated	NULL
transcription	NULL
to	NULL
calcium	NULL
ionophore	NULL
treatment	NULL
may	NULL
be	NULL
specific	NULL
for	NULL
T	NULL
lymphocytes	NULL
since	NULL
in	NULL
a	NULL
pre-B	NULL
cell	NULL
line	NULL
70Z/3	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
any	NULL
augmentation	NULL
of	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
by	NULL
ionomycin	NULL
treatment	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

Furthermore	NULL
,	NULL
NFxB	NULL
was	NULL
not	NULL
sensitive	NULL
to	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
in	NULL
702/3	NULL
cells	NULL
(	NULL
Figure	NULL
5b	NULL
)	NULL
.	NULL

An	NULL
association	NULL
between	NULL
Ca**	NULL
mobilization	NULL
and	NULL
the	NULL
effect	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
was	NULL
also	NULL
observed	NULL
with	NULL
other	NULL
transcription	NULL
factors	NULL
.	NULL

A	NULL
small	NULL
but	NULL
significant	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF-AT	NULL
was	NULL
generated	NULL
by	NULL
ionomycin	NULL
treatment	NULL
alone	NULL
and	NULL
this	NULL
activity	NULL
was	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
(	NULL
Figure	NULL
Sa	NULL
)	NULL
.	NULL

Transcriptional	NULL
activities	NULL
of	NULL
the	NULL
4427	NULL
P.Mattila	NULL
et	NULL
al	NULL
.	NULL

a	NULL
)	NULL
b	NULL
)	NULL
C	NULL
)	NULL
PMA+IONO	NULL
.	NULL

o	NULL
PMA+IONO	NULL
.	NULL

4	NULL
.	NULL

PMA+IONO	NULL
.	NULL

g	NULL
p	NULL
E	NULL
gee	NULL
@	NULL
}	NULL
--	NULL
Amere	NULL
g	NULL
$	NULL
--	NULL
-	NULL
€	NULL
Z	NULL
FK506	NULL
CsA	NULL
IL	NULL
.	NULL

h	NULL
FK506	NULL
CsA	NULL
C.	NULL
2	NULL
FK506	NULL
C	NULL
conc	NULL
.	NULL

of	NULL
~s	NULL
conc	NULL
.	NULL

of	NULL
=	NULL
conc	NULL
.	NULL

of	NULL
-	NULL
-	NULL
01	NULL
1	NULL
10	NULL
1	NULL
10100	NULL
-	NULL
drug	NULL
-	NULL
0.4	NULL
1	NULL
10	NULL
1	NULL
10100	NULL
-	NULL
drug	NULL
-	NULL
-	NULL
01	NULL
1	NULL
10	NULL
--	NULL
drug	NULL
gue	NULL
gur	NULL
|	NULL
;	NULL
dut	NULL
'	NULL
NF-AT	NULL
y	NULL
y	NULL
°	NULL
AP-1	NULL
tig	NULL
NFIL2	NULL
B	NULL
preemie	NULL
c	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

The	NULL
effect	NULL
of	NULL
FK506	NULL
and	NULL
cyclosporin	NULL
A	NULL
on	NULL
the	NULL
development	NULL
of	NULL
DNA	NULL
binding	NULL
activities	NULL
of	NULL
NF-AT	NULL
(	NULL
a	NULL
)	NULL
,	NULL
NFIL2B	NULL
(	NULL
b	NULL
)	NULL
and	NULL
AP-1	NULL
(	NULL
c	NULL
)	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
(	NULL
nM	NULL
)	NULL
and	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
measured	NULL
with	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

NS	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
PMA+IONO	NULL
,	NULL
stimulated	NULL
with	NULL
2	NULL
uM	NULL
ionomycin	NULL
and	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
PMA	NULL
,	NULL
stimulated	NULL
with	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
.	NULL

Inducible	NULL
bands	NULL
are	NULL
indicated	NULL
with	NULL
arrows	NULL
.	NULL

i	NULL
b	NULL
)	NULL
__	NULL
g	NULL
_pma	NULL
_	NULL
_pmariono	NULL
.	NULL

c	NULL
)	NULL
4	NULL
__	NULL
pma	NULL
PMa+lono	NULL
.	NULL

s	NULL
3	NULL
oi	NULL
.	NULL

10	NULL
i	NULL
oio0	NULL
FKsos	NULL
_	NULL
7	NULL
--	NULL
-	NULL
_i	NULL
_	NULL
=	NULL
5	NULL
%	NULL
;	NULL
Saima	NULL
ss	NULL
snim	NULL
DGal	NULL
-\	NULL
-	NULL
)	NULL
10	NULL
04	NULL
10	NULL
1	NULL
0.1	NULL
0.01	NULL
FK506	NULL
``	NULL
_o	NULL
27	NULL
22	NULL
23	NULL
2410038	NULL
55	NULL
90100	NULL
--	NULL
p	NULL
poem	NULL
mo-	NULL
--	NULL
-	NULL
Sl	NULL
l-	NULL
|	NULL
4	NULL
F	NULL
;	NULL
|=	NULL
»	NULL
|tacz	NULL
rna	NULL
|	NULL
_	NULL
W	NULL
@	NULL
”	NULL
ﬁnnﬂwﬂﬁ	NULL
ee	NULL
aad	NULL
mg.	NULL
wes	NULL
Ck	NULL
tut	NULL
ue	NULL
use	NULL
tnd	NULL
inad	NULL
|	NULL
The	NULL
NFKB-lacZ	NULL
Construct	NULL
-	NULL
|e	NULL
NFB	NULL
site	NULL
from	NULL
Ig	NULL
x	NULL
gene	NULL
GATCTCAGAGGGGACTTTCCGAG	NULL
\	NULL
&	NULL
aP	NULL
/	NULL
``	NULL
/	NULL
«	NULL
r	NULL
IL-2	NULL
(	NULL
-72	NULL
to	NULL
+47	NULL
)	NULL
|	NULL
|	NULL
|	NULL
|	NULL
|	NULL
Fig	NULL
.	NULL

4	NULL
.	NULL

(	NULL
a	NULL
)	NULL
The	NULL
NFxB-lacZ	NULL
construct	NULL
has	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NFxB	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
(	NULL
-72	NULL
to	NULL
+45	NULL
)	NULL
directing	NULL
transcription	NULL
of	NULL
the	NULL
E.coli	NULL
lacZ	NULL
-galactosidase	NULL
gene	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Ca**	NULL
dependent	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
is	NULL
inhibited	NULL
by	NULL
FK506	NULL
.	NULL

Jurkat	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
NFxB-lacZ	NULL
construct	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
h	NULL
either	NULL
with	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
alone	NULL
or	NULL
together	NULL
with	NULL
calcium	NULL
ionophore	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
concentrations	NULL
of	NULL
FK506	NULL
(	NULL
nM	NULL
)	NULL
.	NULL

Transcription	NULL
from	NULL
the	NULL
NFxB-/acZ	NULL
construct	NULL
was	NULL
measured	NULL
by	NULL
a	NULL
ribonuclease	NULL
protection	NULL
assay	NULL
.	NULL

The	NULL
size	NULL
of	NULL
the	NULL
probe	NULL
sequence	NULL
protected	NULL
by	NULL
lacZ	NULL
mRNA	NULL
(	NULL
173	NULL
bp	NULL
)	NULL
indicates	NULL
correct	NULL
initiation	NULL
from	NULL
the	NULL
transcription	NULL
initiation	NULL
site	NULL
inside	NULL
the	NULL
promoter	NULL
fragment	NULL
from	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
.	NULL

B-galactosidase	NULL
activity	NULL
is	NULL
presented	NULL
as	NULL
percent	NULL
of	NULL
maximal	NULL
activity	NULL
.	NULL

NS	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
PMA	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
PMA	NULL
+ionomycin	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
and	NULL
2	NULL
M	NULL
ionomycin	NULL
.	NULL

Molecular	NULL
weight	NULL
markers	NULL
(	NULL
M.W	NULL
.	NULL
)	NULL

are	NULL
MspI	NULL
digested	NULL
pBR322	NULL
DNA	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
.	NULL

(	NULL
c	NULL
)	NULL
Ca**	NULL
dependent	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
NFxB	NULL
is	NULL
inhibited	NULL
by	NULL
FK506	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
as	NULL
described	NULL
above	NULL
and	NULL
the	NULL
DNA	NULL
binding	NULL
activity	NULL
was	NULL
measured	NULL
using	NULL
an	NULL
electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
.	NULL

The	NULL
NFxB	NULL
specific	NULL
bands	NULL
are	NULL
indicated	NULL
by	NULL
an	NULL
arrow	NULL
.	NULL

The	NULL
abbreviations	NULL
are	NULL
as	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
4B	NULL
.	NULL

|	NULL
|	NULL
|	NULL
|	NULL
3	NULL
x	NULL
NFKB	NULL
B	NULL
Gal	NULL
‘	NULL
|	NULL
|	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
dependent	NULL
activation	NULL
of	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
is	NULL
not	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
interleukin	NULL
2	NULL
control	NULL
region	NULL
from	NULL
-326	NULL
to	NULL
+47	NULL
,	NULL
NFILZA	NULL
and	NULL
NFIL2B	NULL
required	NULL
stimulation	NULL
with	NULL
both	NULL
ionomycin	NULL
and	NULL
phorbol	NULL
ester	NULL
as	NULL
did	NULL
the	NULL
full	NULL
transcriptional	NULL
activity	NULL
of	NULL
NF	NULL
AT	NULL
and	NULL
all	NULL
these	NULL
activities	NULL
were	NULL
completely	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
(	NULL
Figure	NULL
5a	NULL
)	NULL
.	NULL

4428	NULL
Not	NULL
all	NULL
signalling	NULL
pathways	NULL
regulated	NULL
by	NULL
increased	NULL
intracellular	NULL
Ca**	NULL
were	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
.	NULL

Signal	NULL
transduction	NULL
in	NULL
T	NULL
lymphocyte	NULL
activation	NULL
a	NULL
)	NULL
>	NULL
-	NULL
|IL2	NULL
NF-AT	NULL
NFIL2	NULL
A	NULL
3	NULL
100	NULL
3	NULL
b	NULL
)	NULL
0	NULL
F4	NULL
707	NULL
/	NULL
NF	NULL
kappa	NULL
B	NULL
C	NULL
50	NULL
8	NULL
100	NULL
®	NULL
&	NULL
a	NULL
#	NULL
owo	NULL
o	NULL
#	NULL
#	NULL
#	NULL
|	NULL
#	NULL
#	NULL
wow	NULL
>	NULL
o	NULL
0	NULL
3	NULL
g	NULL
NFIL2	NULL
B	NULL
NF	NULL
kappa	NULL
B	NULL
|	NULL
AP-1+SP-1	NULL
®	NULL
$	NULL
100	NULL
a	NULL
3	NULL
=	NULL
a	NULL
§	NULL
3=	NULL
©	NULL
C	NULL
*	NULL
3	NULL
4	NULL
g	NULL
w	NULL
#	NULL
g	NULL
§	NULL
o	NULL
Pam	NULL
.	NULL

&	NULL
0	NULL
g\qq	NULL
}	NULL
cf¥§\qq	NULL
>	NULL
JQl—§\QQ	NULL
>	NULL
J	NULL
$	NULL
$	NULL
&	NULL
J	NULL
&	NULL
k	NULL
;	NULL
f	NULL
£	NULL
x	NULL
¥	NULL
x	NULL
¥	NULL
x	NULL
2	NULL
C	NULL
*	NULL
y	NULL
Z	NULL
a	NULL
<	NULL
a*	NULL
<	NULL
a*	NULL
<	NULL
a	NULL
&	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Stimulation	NULL
requirements	NULL
for	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
by	NULL
NF-AT	NULL
,	NULL
NFIL2A	NULL
,	NULL
NFIL2B	NULL
,	NULL
NFxB	NULL
,	NULL
AP-1	NULL
and	NULL
SP-1	NULL
transcription	NULL
factors	NULL
and	NULL
by	NULL
a	NULL
control	NULL
region	NULL
of	NULL
interleukin	NULL
2	NULL
gene	NULL
.	NULL

Jurkat	NULL
cells	NULL
stably	NULL
transfected	NULL
with	NULL
constructs	NULL
described	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
2	NULL
containing	NULL
various	NULL
regions	NULL
controlling	NULL
the	NULL
transcription	NULL
of	NULL
E.coli	NULL
lacZ	NULL
were	NULL
stimulated	NULL
for	NULL
5	NULL
h	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
indicated	NULL
drugs	NULL
.	NULL

The	NULL
bars	NULL
present	NULL
the	NULL
mean	NULL
of	NULL
-galactosidase	NULL
activities	NULL
of	NULL
three	NULL
different	NULL
clones	NULL
derived	NULL
from	NULL
independent	NULL
transfections	NULL
except	NULL
in	NULL
the	NULL
case	NULL
of	NULL
NFIL2B	NULL
(	NULL
two	NULL
independent	NULL
clones	NULL
)	NULL
and	NULL
AP-1	NULL
(	NULL
one	NULL
clone	NULL
)	NULL
.	NULL

B-galactosidase	NULL
activity	NULL
is	NULL
presented	NULL
as	NULL
the	NULL
percentage	NULL
of	NULL
the	NULL
maximal	NULL
activity	NULL
of	NULL
each	NULL
cell	NULL
line	NULL
.	NULL

Error	NULL
bars	NULL
present	NULL
standard	NULL
deviations	NULL
,	NULL
a	NULL
star	NULL
indicates	NULL
a	NULL
standard	NULL
deviation	NULL
<	NULL
3	NULL
%	NULL
.	NULL

NS	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
I	NULL
,	NULL
2	NULL
1M	NULL
ionomycin	NULL
;	NULL
P	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
CsA	NULL
,	NULL
100	NULL
nM	NULL
cyclosporin	NULL
A	NULL
;	NULL
FK	NULL
,	NULL
10	NULL
nM	NULL
FK506	NULL
.	NULL

(	NULL
b	NULL
)	NULL
NFxB	NULL
activity	NULL
in	NULL
a	NULL
pre-B	NULL
cell	NULL
line	NULL
702/3	NULL
is	NULL
not	NULL
sensitive	NULL
to	NULL
calcium	NULL
ionophore	NULL
,	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
treatment	NULL
.	NULL

The	NULL
bars	NULL
present	NULL
the	NULL
mean	NULL
of	NULL
-galactosidase	NULL
activities	NULL
of	NULL
two	NULL
different	NULL
clones	NULL
.	NULL

The	NULL
two	NULL
clones	NULL
were	NULL
stably	NULL
transfected	NULL
with	NULL
the	NULL
NFxB-lacZ	NULL
construct	NULL
(	NULL
Figure	NULL
4a	NULL
)	NULL
and	NULL
the	NULL
clones	NULL
were	NULL
derived	NULL
from	NULL
independent	NULL
transfections	NULL
.	NULL

Error	NULL
bars	NULL
present	NULL
standard	NULL
deviations	NULL
.	NULL

Abbreviations	NULL
are	NULL
explained	NULL
in	NULL
the	NULL
legend	NULL
to	NULL
Figure	NULL
5a	NULL
.	NULL

Ca	NULL
'	NULL
*	NULL
ionophore	NULL
enhanced	NULL
the	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
by	NULL
~	NULL
3-fold	NULL
over	NULL
the	NULL
induction	NULL
seen	NULL
with	NULL
phorbol	NULL
ester	NULL
alone	NULL
.	NULL

However	NULL
,	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
level	NULL
of	NULL
c-fos	NULL
expression	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
FK506	NULL
did	NULL
not	NULL
affect	NULL
the	NULL
calcium	NULL
ionophore	NULL
dependent	NULL
DNA	NULL
binding	NULL
activity	NULL
of	NULL
AP-1	NULL
(	NULL
Figure	NULL
3c¢c	NULL
)	NULL
.	NULL

The	NULL
AP-1	NULL
binding	NULL
site	NULL
is	NULL
recognized	NULL
by	NULL
a	NULL
heterodimer	NULL
of	NULL
c-jun	NULL
and	NULL
c-fos	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
activation	NULL
of	NULL
transcription	NULL
(	NULL
Halazonetis	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
finding	NULL
that	NULL
the	NULL
Ca**	NULL
regulated	NULL
transcriptional	NULL
activity	NULL
of	NULL
AP-1	NULL
was	NULL
not	NULL
affected	NULL
by	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
is	NULL
consistent	NULL
with	NULL
the	NULL
finding	NULL
that	NULL
the	NULL
Ca**	NULL
mobilization	NULL
dependent	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
FK506	NULL
(	NULL
Figure	NULL
6	NULL
)	NULL
.	NULL

Requirement	NULL
of	NULL
protein	NULL
synthesis	NULL
for	NULL
transcriptional	NULL
activities	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
We	NULL
investigated	NULL
whether	NULL
protein	NULL
synthesis	NULL
is	NULL
required	NULL
for	NULL
the	NULL
signalling	NULL
pathway	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Ribonuclease	NULL
protection	NULL
assays	NULL
were	NULL
performed	NULL
to	NULL
quantitate	NULL
lacZ	NULL
mRNA	NULL
transcribed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
NFIL2A	NULL
,	NULL
NFIL2B	NULL
and	NULL
NFxB	NULL
transcription	NULL
factors	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
,	NULL
anisomycin	NULL
.	NULL

Transcriptional	NULL
activities	NULL
of	NULL
NFIL2A	NULL
and	NULL
NFIL2B	NULL
were	NULL
inhibited	NULL
by	NULL
anisomycin	NULL
as	NULL
quantitated	NULL
by	NULL
lacZ	NULL
mRNA	NULL
transcribed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
NFILZA	NULL
or	NULL
NFIL2B	NULL
transcription	NULL
factors	NULL
(	NULL
Figure	NULL
7b	NULL
and	NULL
c	NULL
)	NULL
.	NULL

Figure	NULL
7	NULL
also	NULL
shows	NULL
that	NULL
interleukin	NULL
2	NULL
mRNA	NULL
expression	NULL
induced	NULL
by	NULL
Ca**	NULL
mobilization	NULL
and	NULL
phorbol	NULL
ester	NULL
is	NULL
blocked	NULL
by	NULL
inhibition	NULL
of	NULL
protein	NULL
synthesis	NULL
as	NULL
has	NULL
previously	NULL
been	NULL
demonstrated	NULL
(	NULL
Shaw	NULL
n	NULL
60	NULL
min	NULL
~	NULL
Paur	NULL
==	NULL
cP	NULL
cP	NULL
o	NULL
``	NULL
A	NULL
S	NULL
sar	NULL
o	NULL
Y	NULL
Qe	NULL
y	NULL
,	NULL
pC	NULL
ye	NULL
q	NULL
&	NULL
a	NULL
``	NULL
¢	NULL
x	NULL
@	NULL
*	NULL
<	NULL
q	NULL
g	NULL
g	NULL
``	NULL
¢	NULL
``	NULL
|	NULL
#	NULL
#	NULL
#	NULL
c-fos	NULL
~	NULL
|	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

Cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
do	NULL
not	NULL
inhibit	NULL
calcium	NULL
ionophore	NULL
mediated	NULL
signals	NULL
to	NULL
c-fos	NULL
mRNA	NULL
expression	NULL
.	NULL

Jurkat	NULL
cells	NULL
were	NULL
stimulated	NULL
for	NULL
30	NULL
and	NULL
60	NULL
min	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
was	NULL
analyzed	NULL
by	NULL
ribonuclease	NULL
protection	NULL
.	NULL

NS	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
P	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
P+1	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
and	NULL
2	NULL
aM	NULL
ionomycin	NULL
;	NULL
P+I+CsA	NULL
,	NULL
P+I	NULL
and	NULL
100	NULL
nM	NULL
cyclosporin	NULL
A	NULL
;	NULL
P+I+FK	NULL
,	NULL
P+I	NULL
and	NULL
10	NULL
nM	NULL
FK506	NULL
.	NULL

Molecular	NULL
weight	NULL
markers	NULL
(	NULL
M.W	NULL
.	NULL
)	NULL

are	NULL
MspI	NULL
digested	NULL
pBR322	NULL
DNA	NULL
(	NULL
New	NULL
England	NULL
Biolabs	NULL
)	NULL
.	NULL

et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
produced	NULL
by	NULL
phorbol	NULL
ester	NULL
treatment	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
anisomycin	NULL
(	NULL
lanes	NULL
3	NULL
and	NULL
4	NULL
,	NULL
Figure	NULL
7a	NULL
)	NULL
but	NULL
the	NULL
Ca**	NULL
dependent	NULL
transcriptional	NULL
activity	NULL
produced	NULL
by	NULL
treatment	NULL
with	NULL
phorbol	NULL
ester	NULL
together	NULL
with	NULL
ionomycin	NULL
was	NULL
significantly	NULL
inhibited	NULL
by	NULL
anisomycin	NULL
(	NULL
lanes	NULL
7	NULL
and	NULL
8	NULL
,	NULL
Figure	NULL
7b	NULL
)	NULL
.	NULL

However	NULL
,	NULL
FK506	NULL
was	NULL
able	NULL
further	NULL
to	NULL
inhibit	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
even	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
anisomycin	NULL
(	NULL
lanes	NULL
8	NULL
and	NULL
10	NULL
,	NULL
Figure	NULL
7a	NULL
)	NULL
.	NULL

4429	NULL
P.Mattila	NULL
et	NULL
al	NULL
.	NULL

0	NULL
N.S	NULL
PMA+IONO	NULL
+	NULL
+	NULL
CsA	NULL
+	NULL
+	NULL
FK506	NULL
*	NULL
(	NULL
masih	NULL
+	NULL
anisomycin	NULL
+	NULL
anisomycin	NULL
'	NULL
e	NULL
N	NULL
PMA	NULL
PMA+IONO	NULL
te	NULL
<	NULL
-lacZ	NULL
RNA	NULL
|	NULL
lacZ	NULL
RNA	NULL
+	NULL
+	NULL
=	NULL
4	NULL
4	NULL
FK506	NULL
|	NULL
(	NULL
controlled	NULL
(	NULL
controlled	NULL
F	NULL
+	NULL
+	NULL
*	NULL
yamsomya	NULL
,	NULL
‘	NULL
1	NULL
|	NULL
by	NULL
NFIL2	NULL
A	NULL
)	NULL
|	NULL
by	NULL
NFIL2	NULL
B	NULL
2	NULL
20	NULL
22220	NULL
.	NULL

___J	NULL
lacZ	NULL
RNA	NULL
4	NULL
5	NULL
6	NULL
7	NULL
s	NULL
9	NULL
10	NULL
(	NULL
controlled	NULL
by	NULL
NFKB	NULL
)	NULL
t	NULL
a	NULL
am	NULL
!	NULL

-	NULL
@	NULL
4-6-0	NULL
``	NULL
``	NULL
_	NULL
``	NULL
``	NULL
j	NULL
o-fos	NULL
RNA	NULL
11	NULL
12	NULL
13	NULL
14	NULL
15	NULL
16	NULL
17	NULL
18	NULL
19	NULL
20	NULL
win	NULL
*	NULL
#	NULL
|__	NULL
e	NULL
|	NULL
y	NULL
C0	NULL
IL-2	NULL
RNA	NULL
a	NULL
pee	NULL
|	NULL
IL-2	NULL
RNA	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

(	NULL
a	NULL
)	NULL
Ca**	NULL
dependent	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
requires	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

Jurkat	NULL
cells	NULL
that	NULL
contained	NULL
stable	NULL
integrants	NULL
of	NULL
the	NULL
NFxB-lacZ	NULL
construct	NULL
(	NULL
described	NULL
in	NULL
Figure	NULL
4a	NULL
)	NULL
were	NULL
stimulated	NULL
for	NULL
90	NULL
min	NULL
with	NULL
phorbol	NULL
ester	NULL
or	NULL
with	NULL
phorbol	NULL
ester	NULL
together	NULL
with	NULL
calcium	NULL
ionophore	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
FK506	NULL
and	NULL
anisomycin	NULL
.	NULL

The	NULL
amount	NULL
of	NULL
lacZ	NULL
and	NULL
c-fos	NULL
mRNA	NULL
was	NULL
quantitated	NULL
by	NULL
a	NULL
ribonuclease	NULL
protection	NULL
assay	NULL
.	NULL

In	NULL
each	NULL
instance	NULL
anisomycin	NULL
treatment	NULL
increased	NULL
the	NULL
amount	NULL
of	NULL
c-fos	NULL
mRNA	NULL
indicating	NULL
inhibition	NULL
of	NULL
protein	NULL
synthesis	NULL
(	NULL
Greenberg	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1986	NULL
)	NULL
.	NULL

NS	NULL
,	NULL
no	NULL
stimulation	NULL
;	NULL
PMA	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
;	NULL
PMA	NULL
+ionomycin	NULL
,	NULL
32	NULL
nM	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
and	NULL
2	NULL
4M	NULL
ionomycin	NULL
;	NULL
FK506	NULL
,	NULL
10	NULL
nM	NULL
FK506	NULL
;	NULL
anisomycin	NULL
,	NULL
100	NULL
uM	NULL
anisomycin	NULL
.	NULL

(	NULL
b	NULL
and	NULL
¢	NULL
)	NULL
Protein	NULL
synthesis	NULL
is	NULL
required	NULL
for	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFIL2A	NULL
and	NULL
NFIL2B	NULL
.	NULL

(	NULL
b	NULL
)	NULL
Jurkat	NULL
cells	NULL
with	NULL
stable	NULL
integrants	NULL
of	NULL
lacZ	NULL
transcribed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NFIL2A	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
the	NULL
7	NULL
fibrinogen	NULL
promoter	NULL
and	NULL
(	NULL
c	NULL
)	NULL
cells	NULL
with	NULL
stable	NULL
integrants	NULL
of	NULL
lacZ	NULL
transcribed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NFIL2B	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
interleukin	NULL
2	NULL
minimal	NULL
promoter	NULL
were	NULL
stimulated	NULL
for	NULL
90	NULL
min	NULL
with	NULL
phorbol	NULL
ester	NULL
and	NULL
calcium	NULL
ionophore	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
anisomycin	NULL
and	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
.	NULL

lacZ	NULL
mRNA	NULL
was	NULL
quantitated	NULL
by	NULL
a	NULL
ribonuclease	NULL
protection	NULL
assay	NULL
.	NULL

Increased	NULL
levels	NULL
of	NULL
c-fos	NULL
RNA	NULL
were	NULL
also	NULL
seen	NULL
in	NULL
those	NULL
samples	NULL
treated	NULL
with	NULL
anisomycin	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CsA	NULL
,	NULL
100	NULL
nM	NULL
cyclosporin	NULL
;	NULL
other	NULL
abbreviations	NULL
are	NULL
as	NULL
for	NULL
(	NULL
a	NULL
)	NULL
above	NULL
.	NULL

Discussion	NULL
We	NULL
have	NULL
shown	NULL
that	NULL
both	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
several	NULL
transcription	NULL
factors	NULL
involved	NULL
in	NULL
the	NULL
activation	NULL
of	NULL
T	NULL
lymphocytes	NULL
and	NULL
that	NULL
the	NULL
effects	NULL
of	NULL
these	NULL
compounds	NULL
are	NULL
indistinguishable	NULL
except	NULL
for	NULL
a	NULL
consistent	NULL
100-fold	NULL
difference	NULL
in	NULL
their	NULL
effective	NULL
concentration	NULL
.	NULL

Fifty	NULL
percent	NULL
inhibition	NULL
of	NULL
transcription	NULL
was	NULL
observed	NULL
at	NULL
concentrations	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
that	NULL
are	NULL
close	NULL
to	NULL
their	NULL
binding	NULL
constants	NULL
to	NULL
cyclophilin	NULL
and	NULL
FKBP	NULL
,	NULL
respectively	NULL
,	NULL
supporting	NULL
previous	NULL
reports	NULL
which	NULL
suggest	NULL
that	NULL
cyclophilin	NULL
and	NULL
FKBP	NULL
mediate	NULL
the	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
,	NULL
respectively	NULL
(	NULL
Handschumacher	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
;	NULL
Harding	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
;	NULL
Siekierka	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

All	NULL
the	NULL
transcriptional	NULL
activities	NULL
that	NULL
were	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
required	NULL
increased	NULL
intracellular	NULL
Ca'*	NULL
.	NULL

The	NULL
strong	NULL
correlation	NULL
between	NULL
a	NULL
requirement	NULL
for	NULL
Ca	NULL
``	NULL
*	NULL
mobilization	NULL
and	NULL
sensitivity	NULL
to	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
suggests	NULL
that	NULL
these	NULL
drugs	NULL
interfere	NULL
with	NULL
the	NULL
activity	NULL
of	NULL
a	NULL
regulated	NULL
signalling	NULL
pathway	NULL
.	NULL

However	NULL
,	NULL
only	NULL
a	NULL
subset	NULL
of	NULL
Ca**	NULL
regulated	NULL
signalling	NULL
pathways	NULL
is	NULL
affected	NULL
by	NULL
cyclosporin	NULL
A	NULL
or	NULL
FK506	NULL
since	NULL
the	NULL
regulated	NULL
expression	NULL
of	NULL
c-fos	NULL
mRNA	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
these	NULL
drugs	NULL
.	NULL

The	NULL
Ca**	NULL
mobilization-dependent	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
was	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
and	NULL
it	NULL
was	NULL
also	NULL
partially	NULL
inhibited	NULL
by	NULL
a	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
.	NULL

Previously	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
be	NULL
independent	NULL
of	NULL
new	NULL
protein	NULL
synthesis	NULL
(	NULL
Sen	NULL
and	NULL
Baltimore	NULL
,	NULL
1986	NULL
)	NULL
.	NULL

Signal	NULL
transduction	NULL
through	NULL
NFxB	NULL
can	NULL
be	NULL
initiated	NULL
by	NULL
the	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
which	NULL
leads	NULL
to	NULL
the	NULL
dissociation	NULL
of	NULL
NFxB	NULL
from	NULL
IxB	NULL
in	NULL
the	NULL
cytoplasm	NULL
and	NULL
to	NULL
the	NULL
translocation	NULL
of	NULL
active	NULL
NFxB	NULL
into	NULL
the	NULL
nucleus	NULL
,	NULL
a	NULL
process	NULL
which	NULL
does	NULL
not	NULL
require	NULL
new	NULL
protein	NULL
synthesis	NULL
4430	NULL
(	NULL
Bauerle	NULL
and	NULL
Baltimore	NULL
,	NULL
1988	NULL
)	NULL
.	NULL

It	NULL
is	NULL
possible	NULL
that	NULL
co-stimulation	NULL
with	NULL
calcium	NULL
ionophore	NULL
and	NULL
phorbol	NULL
ester	NULL
leads	NULL
additionally	NULL
to	NULL
the	NULL
transcription	NULL
of	NULL
new	NULL
NFxB	NULL
or	NULL
to	NULL
the	NULL
transcription	NULL
of	NULL
a	NULL
factor	NULL
similar	NULL
to	NULL
NFxB	NULL
.	NULL

This	NULL
effect	NULL
may	NULL
be	NULL
specific	NULL
for	NULL
T	NULL
lymphocytes	NULL
since	NULL
we	NULL
did	NULL
not	NULL
detect	NULL
such	NULL
a	NULL
Ca**	NULL
dependent	NULL
augmentation	NULL
in	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
in	NULL
the	NULL
pre	NULL
B	NULL
cell	NULL
line	NULL
,	NULL
702/3	NULL
.	NULL

Although	NULL
the	NULL
activity	NULL
of	NULL
some	NULL
subspecies	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
are	NULL
sensitive	NULL
to	NULL
(	NULL
Nishizuka	NULL
,	NULL
1988	NULL
)	NULL
the	NULL
finding	NULL
that	NULL
the	NULL
dependent	NULL
activity	NULL
of	NULL
NFxB	NULL
required	NULL
new	NULL
protein	NULL
synthesis	NULL
indicates	NULL
that	NULL
a	NULL
direct	NULL
activation	NULL
of	NULL
protein	NULL
kinase	NULL
C	NULL
by	NULL
increased	NULL
intracellular	NULL
Ca**	NULL
does	NULL
not	NULL
completely	NULL
explain	NULL
the	NULL
observed	NULL
Ca'*	NULL
dependent	NULL
activity	NULL
of	NULL
NFxB	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Recently	NULL
,	NULL
Schmidt	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
have	NULL
also	NULL
reported	NULL
that	NULL
the	NULL
activation	NULL
of	NULL
NFxB	NULL
is	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
in	NULL
a	NULL
signal	NULL
dependent	NULL
manner	NULL
.	NULL

Since	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK	NULL
506	NULL
inhibit	NULL
the	NULL
peptidyl-prolyl	NULL
cis-trans	NULL
isomerase	NULL
activities	NULL
of	NULL
cyclophilin	NULL
and	NULL
FKBP	NULL
respectively	NULL
,	NULL
the	NULL
inhibited	NULL
isomerase	NULL
activities	NULL
might	NULL
mediate	NULL
the	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Proline	NULL
cis-trans	NULL
isomerism	NULL
has	NULL
been	NULL
proposed	NULL
to	NULL
regulate	NULL
other	NULL
processes	NULL
,	NULL
namely	NULL
the	NULL
activity	NULL
of	NULL
transport	NULL
proteins	NULL
(	NULL
Brand	NULL
]	NULL
and	NULL
Deber	NULL
,	NULL
1986	NULL
)	NULL
,	NULL
binding	NULL
of	NULL
concanavalin	NULL
A	NULL
to	NULL
sugar	NULL
residues	NULL
(	NULL
Brown	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1977	NULL
)	NULL
and	NULL
binding	NULL
of	NULL
prothrombin	NULL
fragment	NULL
1	NULL
to	NULL
phospholipid	NULL
(	NULL
Marsh	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1979	NULL
)	NULL
.	NULL

Peptidyl-prolyl	NULL
cis-trans	NULL
isomerase	NULL
activity	NULL
has	NULL
been	NULL
reported	NULL
to	NULL
affect	NULL
the	NULL
folding	NULL
of	NULL
proteins	NULL
in	NULL
vitro	NULL
(	NULL
Lang	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
;	NULL
Lin	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
and	NULL
thus	NULL
it	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
refolding	NULL
of	NULL
new	NULL
proteins	NULL
in	NULL
vivo	NULL
after	NULL
synthesis	NULL
on	NULL
the	NULL
ribosome	NULL
.	NULL

If	NULL
this	NULL
is	NULL
the	NULL
case	NULL
,	NULL
the	NULL
effect	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
may	NULL
therefore	NULL
be	NULL
associated	NULL
with	NULL
events	NULL
that	NULL
require	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

Although	NULL
transcriptional	NULL
activities	NULL
of	NULL
NF-AT	NULL
(	NULL
Shaw	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
,	NULL
NFILZA	NULL
and	NULL
NFIL2B	NULL
did	NULL
require	NULL
new	NULL
protein	NULL
synthesis	NULL
we	NULL
did	NULL
observe	NULL
a	NULL
small	NULL
inhibitory	NULL
effect	NULL
of	NULL
FK506	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
the	NULL
protein	NULL
synthesis	NULL
inhibitor	NULL
,	NULL
anisomycin	NULL
,	NULL
on	NULL
the	NULL
transcriptional	NULL
activity	NULL
of	NULL
NFxB	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
inhibitory	NULL
effect	NULL
of	NULL
FK506	NULL
on	NULL
transcription	NULL
may	NULL
not	NULL
always	NULL
require	NULL
new	NULL
protein	NULL
synthesis	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
still	NULL
possible	NULL
that	NULL
anisomycin	NULL
did	NULL
not	NULL
completely	NULL
inhibit	NULL
protein	NULL
synthesis	NULL
.	NULL

Recently	NULL
we	NULL
have	NULL
shown	NULL
that	NULL
rapamycin	NULL
,	NULL
which	NULL
is	NULL
structurally	NULL
related	NULL
to	NULL
FK506	NULL
,	NULL
binds	NULL
to	NULL
FKBP	NULL
with	NULL
a	NULL
binding	NULL
affinity	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
FK506	NULL
and	NULL
also	NULL
inhibits	NULL
the	NULL
isomerase	NULL
activity	NULL
of	NULL
FKBP	NULL
(	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
FK506	NULL
,	NULL
rapamycin	NULL
does	NULL
not	NULL
inhibit	NULL
T	NULL
cell	NULL
activation	NULL
induced	NULL
by	NULL
signals	NULL
from	NULL
the	NULL
antigen	NULL
receptor	NULL
but	NULL
,	NULL
on	NULL
the	NULL
contrary	NULL
,	NULL
when	NULL
added	NULL
in	NULL
500-fold	NULL
excess	NULL
reverses	NULL
the	NULL
effect	NULL
of	NULL
FK506	NULL
on	NULL
interleukin	NULL
2	NULL
production	NULL
(	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
;	NULL
Dumont	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
and	NULL
on	NULL
all	NULL
the	NULL
transcription	NULL
factors	NULL
that	NULL
were	NULL
inhibited	NULL
by	NULL
FK506	NULL
(	NULL
P.Mattila	NULL
and	NULL
G.Crabtree	NULL
,	NULL
unpublished	NULL
results	NULL
)	NULL
.	NULL

These	NULL
results	NULL
do	NULL
not	NULL
favor	NULL
the	NULL
involvement	NULL
of	NULL
the	NULL
isomerase	NULL
activity	NULL
in	NULL
signal	NULL
transduction	NULL
in	NULL
T	NULL
lymphocytes	NULL
but	NULL
rather	NULL
can	NULL
be	NULL
explained	NULL
by	NULL
a	NULL
model	NULL
in	NULL
which	NULL
FK506	NULL
forms	NULL
an	NULL
inhibitory	NULL
complex	NULL
with	NULL
FKBP	NULL
that	NULL
interferes	NULL
with	NULL
signal	NULL
transduction	NULL
of	NULL
T	NULL
lymphocytes	NULL
(	NULL
Bierer	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

A	NULL
similar	NULL
model	NULL
which	NULL
includes	NULL
a	NULL
complex	NULL
of	NULL
a	NULL
protein	NULL
homologous	NULL
to	NULL
cyclophilin	NULL
and	NULL
cyclosporin	NULL
A	NULL
has	NULL
previously	NULL
been	NULL
demonstrated	NULL
for	NULL
cyclosporin	NULL
A	NULL
mediated	NULL
toxicity	NULL
in	NULL
N.	NULL
crassa	NULL
and	NULL
S.	NULL
cerevisiae	NULL
(	NULL
Tropschug	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1989	NULL
)	NULL
.	NULL

Since	NULL
cyclophilin	NULL
and	NULL
FKBP	NULL
are	NULL
proline	NULL
isomerases	NULL
and	NULL
thus	NULL
may	NULL
be	NULL
involved	NULL
in	NULL
the	NULL
folding	NULL
of	NULL
several	NULL
proteins	NULL
they	NULL
may	NULL
have	NULL
an	NULL
intrinsic	NULL
characteristic	NULL
of	NULL
interacting	NULL
with	NULL
many	NULL
different	NULL
proteins	NULL
.	NULL

Binding	NULL
to	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
could	NULL
give	NULL
them	NULL
a	NULL
new	NULL
specificity	NULL
to	NULL
interfere	NULL
with	NULL
protein	NULL
(	NULL
s	NULL
)	NULL
important	NULL
in	NULL
signal	NULL
transmission	NULL
in	NULL
T	NULL
lymphocytes	NULL
.	NULL

Cyclophilin	NULL
and	NULL
FKBP	NULL
may	NULL
directly	NULL
interact	NULL
with	NULL
all	NULL
four	NULL
different	NULL
transcription	NULL
factors	NULL
inhibited	NULL
by	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

This	NULL
is	NULL
made	NULL
less	NULL
likely	NULL
by	NULL
the	NULL
observation	NULL
that	NULL
we	NULL
did	NULL
not	NULL
find	NULL
a	NULL
single	NULL
transcription	NULL
factor	NULL
among	NULL
six	NULL
tested	NULL
(	NULL
NF-AT	NULL
,	NULL
NFIL2A	NULL
,	NULL
NFIL2B	NULL
,	NULL
NFxB	NULL
,	NULL
AP-1	NULL
or	NULL
SP-1	NULL
)	NULL
that	NULL
was	NULL
inhibited	NULL
by	NULL
one	NULL
but	NULL
not	NULL
by	NULL
both	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
a	NULL
novel	NULL
Ca	NULL
``	NULL
*	NULL
dependent	NULL
step	NULL
proximal	NULL
to	NULL
the	NULL
transcription	NULL
factors	NULL
in	NULL
signal	NULL
transduction	NULL
of	NULL
T	NULL
lymphocytes	NULL
is	NULL
the	NULL
target	NULL
of	NULL
both	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Materials	NULL
and	NULL
methods	NULL
Plasmids	NULL
The	NULL
£	NULL
.	NULL

coli	NULL
lacZ	NULL
-galactosidase	NULL
gene	NULL
was	NULL
a	NULL
BamHI	NULL
fragment	NULL
of	NULL
PMC1871	NULL
(	NULL
Shapira	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1983	NULL
)	NULL
and	NULL
was	NULL
initially	NULL
cloned	NULL
into	NULL
the	NULL
BamHI	NULL
site	NULL
of	NULL
SP65	NULL
(	NULL
Promega	NULL
)	NULL
.	NULL

The	NULL
initiation	NULL
of	NULL
translation	NULL
was	NULL
derived	NULL
from	NULL
the	NULL
MoMuLV	NULL
envelope	NULL
gene	NULL
and	NULL
was	NULL
cloned	NULL
by	NULL
inserting	NULL
a	NULL
synthetic	NULL
sequence	NULL
CTAGAC-TGACATGGCGGATC	NULL
between	NULL
the	NULL
Xbal	NULL
and	NULL
BamHI	NULL
sites	NULL
of	NULL
SP65	NULL
.	NULL

This	NULL
construct	NULL
,	NULL
called	NULL
was	NULL
constructed	NULL
by	NULL
Constance	NULL
Cepco	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
Boston	NULL
)	NULL
and	NULL
Jack	NULL
Price	NULL
(	NULL
Mill	NULL
Hill	NULL
MRC	NULL
,	NULL
England	NULL
)	NULL
.	NULL

Polyadenylation	NULL
sequence	NULL
and	NULL
small	NULL
t	NULL
intron	NULL
of	NULL
SV40	NULL
was	NULL
derived	NULL
from	NULL
a	NULL
Sall	NULL
and	NULL
HindIII	NULL
fragment	NULL
of	NULL
pko-neo	NULL
(	NULL
van	NULL
Doren	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1984	NULL
)	NULL
.	NULL

An	NULL
Xhol	NULL
linker	NULL
was	NULL
inserted	NULL
inside	NULL
this	NULL
fragment	NULL
into	NULL
a	NULL
BamHI	NULL
site	NULL
3	NULL
'	NULL
of	NULL
the	NULL
polyadenylation	NULL
sequence	NULL
.	NULL

The	NULL
fragment	NULL
was	NULL
blunt	NULL
ended	NULL
by	NULL
Klenow	NULL
fragment	NULL
and	NULL
ligated	NULL
to	NULL
the	NULL
Smal	NULL
site	NULL
of	NULL
SP65	NULL
.	NULL

The	NULL
resulting	NULL
plasmid	NULL
,	NULL
called	NULL
A	NULL
,	NULL
originated	NULL
from	NULL
Jacik	NULL
Skowronski	NULL
(	NULL
Cold	NULL
Spring	NULL
Harbour	NULL
,	NULL
New	NULL
York	NULL
)	NULL
.	NULL

The	NULL
hygromycin	NULL
resistance	NULL
gene	NULL
under	NULL
the	NULL
transcriptional	NULL
control	NULL
of	NULL
herpes	NULL
simplex	NULL
virus	NULL
thymidine	NULL
kinase	NULL
promoter	NULL
was	NULL
derived	NULL
as	NULL
a	NULL
blunt	NULL
ended	NULL
Narl	NULL
-Nrul	NULL
fragment	NULL
from	NULL
pHYg	NULL
(	NULL
Sugden	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1985	NULL
)	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
ligated	NULL
to	NULL
the	NULL
Smal	NULL
site	NULL
of	NULL
pTZ19	NULL
(	NULL
Pharmacia	NULL
)	NULL
and	NULL
a	NULL
Bg/II	NULL
linker	NULL
was	NULL
inserted	NULL
into	NULL
a	NULL
SacI	NULL
site	NULL
filled	NULL
in	NULL
by	NULL
Klenow	NULL
fragment	NULL
of	NULL
the	NULL
pTZ19	NULL
.	NULL

The	NULL
lacZ	NULL
with	NULL
the	NULL
inserted	NULL
initiation	NULL
of	NULL
translation	NULL
and	NULL
polyadenylation	NULL
sequences	NULL
was	NULL
cut	NULL
out	NULL
from	NULL
SP6-SgalpolyA	NULL
with	NULL
HindIII	NULL
and	NULL
Xf	NULL
:	NULL
ol	NULL
and	NULL
ligated	NULL
between	NULL
the	NULL
HindIII	NULL
and	NULL
Sall	NULL
sites	NULL
of	NULL
the	NULL
modified	NULL
pTZ19	NULL
.	NULL

The	NULL
resulting	NULL
plasmid	NULL
Signal	NULL
transduction	NULL
in	NULL
T	NULL
lymphocyte	NULL
activation	NULL
is	NULL
called	NULL
pLacZH	NULL
and	NULL
it	NULL
has	NULL
the	NULL
lacZ	NULL
gene	NULL
5	NULL
'	NULL
of	NULL
the	NULL
hygromycin	NULL
resistance	NULL
gene	NULL
.	NULL

The	NULL
orientations	NULL
of	NULL
transcription	NULL
of	NULL
both	NULL
genes	NULL
are	NULL
the	NULL
same	NULL
.	NULL

The	NULL
fragment	NULL
carrying	NULL
the	NULL
lacZ	NULL
and	NULL
hygromycin	NULL
resistance	NULL
genes	NULL
was	NULL
cleaved	NULL
from	NULL
pLacZH	NULL
with	NULL
HindIII	NULL
and	NULL
Bg/lI	NULL
and	NULL
inserted	NULL
in	NULL
the	NULL
place	NULL
of	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
which	NULL
was	NULL
removed	NULL
with	NULL
HindIII	NULL
and	NULL
BamHI	NULL
from	NULL
the	NULL
following	NULL
plasmids	NULL
:	NULL
pIL2CAT	NULL
(	NULL
Durand	NULL
er	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
which	NULL
has	NULL
sequences	NULL
-326	NULL
to	NULL
+47	NULL
from	NULL
interleukin	NULL
2	NULL
gene	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
chloramphenicol	NULL
acetyltransferase	NULL
gene	NULL
,	NULL
NFAT.22.6	NULL
which	NULL
has	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
the	NULL
interleukin	NULL
2	NULL
promoter	NULL
(	NULL
-72	NULL
to	NULL
+47	NULL
of	NULL
interleukin	NULL
2	NULL
)	NULL
,	NULL
pA	NULL
4.1	NULL
which	NULL
has	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NFIL2A	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
~	NULL
fibrinogen	NULL
minimal	NULL
promoter	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
,	NULL
X	NULL
,	NULL
CAT	NULL
which	NULL
has	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
metallothionein	NULL
gene	NULL
enhancer	NULL
linked	NULL
to	NULL
the	NULL
SV40	NULL
minimal	NULL
promoter	NULL
(	NULL
Lee	NULL
etal	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
,	NULL
KBCAT	NULL
which	NULL
has	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
human	NULL
immunoglobulin	NULL
x	NULL
light	NULL
chain	NULL
x	NULL
B	NULL
site	NULL
ligated	NULL
to	NULL
-72	NULL
of	NULL
interleukin	NULL
2	NULL
minimal	NULL
promoter	NULL
and	NULL
NFIL2BCAT	NULL
which	NULL
has	NULL
four	NULL
copies	NULL
of	NULL
NFIL2B	NULL
binding	NULL
site	NULL
from	NULL
interleukin	NULL
2	NULL
gene	NULL
linked	NULL
to	NULL
interleukin	NULL
2	NULL
minimal	NULL
promoter	NULL
.	NULL

The	NULL
resulting	NULL
plasmids	NULL
were	NULL
called	NULL
pIL2ZH	NULL
,	NULL
NFATZH	NULL
,	NULL
NFIL2AZH	NULL
,	NULL
X	NULL
,	NULL
ZH	NULL
,	NULL
KBZH	NULL
and	NULL
NFIL2BZH	NULL
respectively	NULL
.	NULL

NFAT.22.6	NULL
was	NULL
constructed	NULL
by	NULL
Cor	NULL
Verweij	NULL
by	NULL
inserting	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
NF-AT	NULL
binding	NULL
sequence	NULL
(	NULL
-286	NULL
to	NULL
-257	NULL
of	NULL
interleukin	NULL
2	NULL
gene	NULL
)	NULL
into	NULL
the	NULL
XAol	NULL
site	NULL
of	NULL
p22/6	NULL
which	NULL
was	NULL
a	NULL
deletion	NULL
mutant	NULL
from	NULL
pIL2CAT	NULL
and	NULL
had	NULL
sequences	NULL
between	NULL
-296	NULL
and	NULL
-72	NULL
relative	NULL
to	NULL
interleukin	NULL
2	NULL
transcription	NULL
start	NULL
site	NULL
deleted	NULL
and	NULL
a	NULL
Xhol	NULL
linker	NULL
inserted	NULL
in	NULL
place	NULL
of	NULL
the	NULL
deletion	NULL
(	NULL
Verweij	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1990	NULL
)	NULL
.	NULL

KBCAT	NULL
was	NULL
constructed	NULL
by	NULL
annealing	NULL
oligonucleotides	NULL
gatc	NULL
and	NULL
gatcCTCGGAAAGTCCCCTCTGA	NULL
and	NULL
ligating	NULL
the	NULL
annealed	NULL
product	NULL
with	NULL
itself	NULL
.	NULL

The	NULL
ligation	NULL
product	NULL
was	NULL
filled	NULL
in	NULL
with	NULL
Klenow	NULL
enzyme	NULL
and	NULL
ligated	NULL
to	NULL
the	NULL
filled	NULL
in	NULL
XhoI	NULL
site	NULL
of	NULL
p22/6	NULL
.	NULL

The	NULL
resulting	NULL
plasmid	NULL
contained	NULL
three	NULL
copies	NULL
of	NULL
the	NULL
x	NULL
B	NULL
site	NULL
,	NULL
the	NULL
two	NULL
5	NULL
'	NULL
ones	NULL
in	NULL
the	NULL
reverse	NULL
orientation	NULL
in	NULL
respect	NULL
to	NULL
the	NULL
orientation	NULL
of	NULL
the	NULL
x	NULL
B	NULL
sites	NULL
in	NULL
the	NULL
x	NULL
immunoglobulin	NULL
gene	NULL
.	NULL

NFIL2BCAT	NULL
was	NULL
constructed	NULL
by	NULL
annealing	NULL
oligonucleotides	NULL
tegaCAATT-CCAAAGAGTCATCAGAAGAGGAC	NULL
and	NULL
tegaGTCCTCTTCTGATGA-CTCTTTGGAATTG	NULL
and	NULL
ligating	NULL
the	NULL
double	NULL
stranded	NULL
sequence	NULL
into	NULL
the	NULL
Xhol	NULL
site	NULL
of	NULL
p22/6	NULL
.	NULL

NFIL2BCAT	NULL
has	NULL
four	NULL
copies	NULL
of	NULL
the	NULL
NFIL2B	NULL
binding	NULL
site	NULL
linked	NULL
to	NULL
the	NULL
minimal	NULL
interleukin	NULL
2	NULL
promoter	NULL
in	NULL
the	NULL
same	NULL
orientation	NULL
as	NULL
the	NULL
NFIL2B	NULL
site	NULL
in	NULL
the	NULL
interleukin	NULL
2	NULL
gene	NULL
.	NULL

The	NULL
orientations	NULL
of	NULL
the	NULL
inserted	NULL
genes	NULL
were	NULL
confirmed	NULL
with	NULL
sequencing	NULL
.	NULL

The	NULL
resulting	NULL
plasmids	NULL
were	NULL
linearized	NULL
for	NULL
electroporation	NULL
with	NULL
KpnI	NULL
which	NULL
cuts	NULL
immediately	NULL
3	NULL
'	NULL
of	NULL
the	NULL
hygromycin	NULL
resistance	NULL
gene	NULL
.	NULL

Transfections	NULL
and	NULL
selection	NULL
of	NULL
clones	NULL
Cell	NULL
lines	NULL
with	NULL
stable	NULL
integrants	NULL
of	NULL
the	NULL
constructs	NULL
were	NULL
established	NULL
by	NULL
electroporating	NULL
linearized	NULL
plasmids	NULL
into	NULL
Jurkat	NULL
cells	NULL
and	NULL
selecting	NULL
with	NULL
hygromycin	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
maintained	NULL
in	NULL
complete	NULL
RPMI	NULL
1640	NULL
(	NULL
Gibco	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
v/v	NULL
fetal	NULL
calf	NULL
serum	NULL
,	NULL
100	NULL
U/ml	NULL
penicillin	NULL
and	NULL
50	NULL
U/ml	NULL
streptomycin	NULL
in	NULL
a	NULL
5	NULL
%	NULL
CO	NULL
;	NULL
,	NULL
/95	NULL
%	NULL
air	NULL
atmosphere	NULL
.	NULL

Ten	NULL
million	NULL
cells	NULL
were	NULL
electroporated	NULL
with	NULL
20	NULL
ug	NULL
of	NULL
linearized	NULL
plasmid	NULL
in	NULL
1	NULL
ml	NULL
RPMI	NULL
1640	NULL
using	NULL
a	NULL
250	NULL
V	NULL
and	NULL
960	NULL
F	NULL
electric	NULL
shock	NULL
(	NULL
Gene	NULL
Pulser	NULL
,	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Immediately	NULL
after	NULL
electroporation	NULL
cells	NULL
were	NULL
suspended	NULL
in	NULL
24	NULL
ml	NULL
of	NULL
tissue	NULL
culture	NULL
media	NULL
and	NULL
1	NULL
ml	NULL
aliquots	NULL
were	NULL
added	NULL
into	NULL
a	NULL
24	NULL
well	NULL
plate	NULL
.	NULL

The	NULL
following	NULL
day	NULL
hygromycin	NULL
was	NULL
added	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
culture	NULL
media	NULL
to	NULL
each	NULL
well	NULL
to	NULL
give	NULL
a	NULL
final	NULL
concentration	NULL
of	NULL
200	NULL
ug/ml	NULL
of	NULL
hygromycin	NULL
(	NULL
Calbiochem	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Hygromycin	NULL
containing	NULL
media	NULL
was	NULL
changed	NULL
periodically	NULL
until	NULL
resistant	NULL
cells	NULL
grew	NULL
out	NULL
which	NULL
usually	NULL
occurred	NULL
in	NULL
2	NULL
weeks	NULL
.	NULL

Clones	NULL
expressing	NULL
high	NULL
levels	NULL
of	NULL
lacZ	NULL
after	NULL
stimulation	NULL
were	NULL
selected	NULL
and	NULL
cloned	NULL
using	NULL
fluorescence	NULL
activated	NULL
cell	NULL
sorter	NULL
(	NULL
FACS	NULL
)	NULL
and	NULL
the	NULL
fluorogenic	NULL
substrate	NULL
fluorescein-di-galactoside	NULL
(	NULL
Nolan	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
.	NULL

The	NULL
following	NULL
cell	NULL
clones	NULL
were	NULL
used	NULL
.	NULL

IL2.2A	NULL
,	NULL
1L2.7B	NULL
,	NULL
IL2.11A	NULL
(	NULL
transfected	NULL
with	NULL
IL2ZH	NULL
)	NULL
;	NULL
NFAT.4B	NULL
,	NULL
NFAT.5A	NULL
(	NULL
transfected	NULL
with	NULL
NFATZH	NULL
)	NULL
;	NULL
NFIL2A.4.4	NULL
,	NULL
NFIL2A.11.5	NULL
,	NULL
NFIL2A.20.9	NULL
(	NULL
transfected	NULL
with	NULL
NFIL2AZH	NULL
)	NULL
;	NULL
NFIL2B.6.1	NULL
,	NULL
NFIL2B.11.2	NULL
(	NULL
transfected	NULL
with	NULL
NFIL2BZH	NULL
)	NULL
:	NULL
KB.2.2	NULL
,	NULL
KB.5.2	NULL
,	NULL
KB.7.2	NULL
(	NULL
transfected	NULL
with	NULL
KBZH	NULL
)	NULL
and	NULL
X.7.1	NULL
(	NULL
transfected	NULL
with	NULL
X	NULL
;	NULL
ZH	NULL
)	NULL
.	NULL

The	NULL
cell	NULL
line	NULL
J.NFATZ.1	NULL
that	NULL
was	NULL
transfected	NULL
with	NULL
a	NULL
construct	NULL
containing	NULL
three	NULL
copies	NULL
of	NULL
NF-AT	NULL
binding	NULL
sites	NULL
controlling	NULL
the	NULL
expression	NULL
of	NULL
lacZ	NULL
is	NULL
described	NULL
by	NULL
Fiering	NULL
er	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
J.NFATZ.1	NULL
,	NULL
KB.5.2	NULL
,	NULL
NFIL2B.11.5	NULL
and	NULL
NFIL2B.6.1	NULL
were	NULL
used	NULL
for	NULL
ribonuclease	NULL
protection	NULL
assays	NULL
.	NULL

Stimulation	NULL
of	NULL
cells	NULL
All	NULL
stimulations	NULL
were	NULL
done	NULL
with	NULL
exponentially	NULL
growing	NULL
cells	NULL
whose	NULL
density	NULL
was	NULL
not	NULL
greater	NULL
than	NULL
0.5	NULL
million	NULL
cells/ml	NULL
.	NULL

Cells	NULL
were	NULL
stimulated	NULL
in	NULL
fresh	NULL
tissue	NULL
culture	NULL
media	NULL
at	NULL
a	NULL
density	NULL
no	NULL
higher	NULL
than	NULL
0.7	NULL
million	NULL
cells/ml	NULL
.	NULL

Stock	NULL
solutions	NULL
of	NULL
phorbol	NULL
myristate	NULL
acetate	NULL
(	NULL
Sigma	NULL
)	NULL
and	NULL
ionomycin	NULL
(	NULL
Calbiochem	NULL
)	NULL
were	NULL
prepared	NULL
in	NULL
dimethylsulfoxide	NULL
and	NULL
stock	NULL
solutions	NULL
of	NULL
cyclosporin	NULL
A	NULL
,	NULL
FK506	NULL
and	NULL
anisomycin	NULL
were	NULL
prepared	NULL
in	NULL
ethanol	NULL
and	NULL
stored	NULL
at	NULL
-20°C	NULL
.	NULL

Ribonuclease	NULL
protection	NULL
assay	NULL
KSgal	NULL
which	NULL
was	NULL
a	NULL
template	NULL
for	NULL
the	NULL
lacZ	NULL
RNA	NULL
probe	NULL
was	NULL
constructed	NULL
by	NULL
cutting	NULL
Bluescript	NULL
KS	NULL
(	NULL
-	NULL
)	NULL
vector	NULL
(	NULL
Stratagene	NULL
)	NULL
with	NULL
Smal/Xhol	NULL
and	NULL
inserting	NULL
4431	NULL
P.Mattila	NULL
ot	NULL
al	NULL
.	NULL

a	NULL
Xhol-Pvull	NULL
fragment	NULL
from	NULL
NFATZH	NULL
which	NULL
contains	NULL
promoter	NULL
sequences	NULL
from	NULL
interleukin	NULL
2	NULL
(	NULL
from	NULL
-72	NULL
to	NULL
+47	NULL
)	NULL
and	NULL
lacZ	NULL
sequences	NULL
.	NULL

KSgal	NULL
was	NULL
linearized	NULL
with	NULL
Kprl	NULL
and	NULL
the	NULL
RNA	NULL
probe	NULL
was	NULL
synthesized	NULL
with	NULL
T7	NULL
RNA	NULL
polymerase	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
310	NULL
bp	NULL
long	NULL
and	NULL
a	NULL
172	NULL
bp	NULL
fragment	NULL
was	NULL
protected	NULL
by	NULL
lacZ	NULL
mRNA	NULL
.	NULL

This	NULL
probe	NULL
also	NULL
protected	NULL
a	NULL
47	NULL
bp	NULL
fragment	NULL
of	NULL
endogenous	NULL
interleukin	NULL
2	NULL
mRNA	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
used	NULL
to	NULL
detect	NULL
lacZ	NULL
and	NULL
interleukin	NULL
2	NULL
mRNA	NULL
in	NULL
all	NULL
cell	NULL
lines	NULL
except	NULL
in	NULL
J.NFATZ.1	NULL
which	NULL
contained	NULL
a	NULL
different	NULL
translational	NULL
initiation	NULL
site	NULL
for	NULL
lacZ	NULL
.	NULL

The	NULL
template	NULL
used	NULL
for	NULL
the	NULL
RNA	NULL
probe	NULL
for	NULL
detecting	NULL
lacZ	NULL
RNA	NULL
in	NULL
this	NULL
cell	NULL
line	NULL
is	NULL
described	NULL
by	NULL
Fiering	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
.	NULL

The	NULL
probe	NULL
was	NULL
370	NULL
bp	NULL
long	NULL
and	NULL
the	NULL
fragment	NULL
protected	NULL
by	NULL
lacZ	NULL
mRNA	NULL
was	NULL
250	NULL
bp	NULL
long	NULL
.	NULL

The	NULL
template	NULL
for	NULL
c-fos	NULL
riboprobe	NULL
was	NULL
constructed	NULL
by	NULL
cutting	NULL
a	NULL
200	NULL
bp	NULL
Nsil-Tth111I	NULL
fragment	NULL
from	NULL
the	NULL
3	NULL
'	NULL
untranslated	NULL
region	NULL
of	NULL
the	NULL
human	NULL
c-fos	NULL
gene	NULL
and	NULL
cloning	NULL
this	NULL
fragment	NULL
into	NULL
Psfl	NULL
and	NULL
Smal	NULL
sites	NULL
of	NULL
SP65	NULL
(	NULL
Promega	NULL
)	NULL
by	NULL
first	NULL
filling	NULL
in	NULL
the	NULL
TH	NULL
11	NULL
LI	NULL
site	NULL
by	NULL
Klenow	NULL
enzyme	NULL
.	NULL

The	NULL
resulting	NULL
plasmid	NULL
was	NULL
linearized	NULL
with	NULL
HindIII	NULL
and	NULL
the	NULL
RNA	NULL
probe	NULL
was	NULL
synthesized	NULL
with	NULL
SP6	NULL
RNA	NULL
polymerase	NULL
.	NULL

The	NULL
resulting	NULL
RNA	NULL
probe	NULL
was	NULL
250	NULL
bp	NULL
long	NULL
and	NULL
the	NULL
size	NULL
of	NULL
the	NULL
fragment	NULL
protected	NULL
by	NULL
c-fos	NULL
mRNA	NULL
was	NULL
200	NULL
bp	NULL
.	NULL

Ribonuclease	NULL
protection	NULL
was	NULL
carried	NULL
out	NULL
essentially	NULL
as	NULL
described	NULL
by	NULL
Melton	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
.	NULL

Hybridizations	NULL
were	NULL
done	NULL
at	NULL
42°C	NULL
in	NULL
80	NULL
%	NULL
formamide	NULL
,	NULL
40	NULL
mM	NULL
PIPES	NULL
pH	NULL
6.4	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
400	NULL
mM	NULL
NaCl	NULL
overnight	NULL
in	NULL
30	NULL
l	NULL
using	NULL
10	NULL
ug	NULL
of	NULL
RNA	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
digested	NULL
by	NULL
adding	NULL
300	NULL
al	NULL
of	NULL
5	NULL
ug/ml	NULL
!	NULL

RNase	NULL
A	NULL
,	NULL
120	NULL
U/ml	NULL
RNase	NULL
T1	NULL
,	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
pH	NULL
7.5	NULL
,	NULL
5	NULL
mM	NULL
EDTA	NULL
,	NULL
300	NULL
mM	NULL
NaCl	NULL
and	NULL
letting	NULL
the	NULL
digestion	NULL
proceed	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
digestion	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
20	NULL
xl	NULL
of	NULL
10	NULL
%	NULL
SDS	NULL
and	NULL
the	NULL
samples	NULL
were	NULL
subsequently	NULL
treated	NULL
with	NULL
proteinase	NULL
K	NULL
,	NULL
phenol	NULL
and	NULL
chloroform	NULL
extracted	NULL
,	NULL
precipitated	NULL
with	NULL
ethanol	NULL
,	NULL
dissolved	NULL
in	NULL
4	NULL
pl	NULL
of	NULL
80	NULL
%	NULL
formamide	NULL
and	NULL
electrophoresed	NULL
in	NULL
a	NULL
6	NULL
%	NULL
denaturing	NULL
polyacrylamide	NULL
gel	NULL
.	NULL

-Galactosidase	NULL
assay	NULL
B-Galactosidase	NULL
activity	NULL
was	NULL
measured	NULL
as	NULL
the	NULL
fluorescence	NULL
generated	NULL
by	NULL
the	NULL
cleavage	NULL
of	NULL
4-methylumbellifery1-3-p-galactoside	NULL
(	NULL
Sigma	NULL
)	NULL
at	NULL
the	NULL
B-galactoside	NULL
bond	NULL
.	NULL

Fifty	NULL
thousand	NULL
cells	NULL
were	NULL
stimulated	NULL
in	NULL
200	NULL
gl	NULL
fresh	NULL
culture	NULL
media	NULL
in	NULL
96	NULL
well	NULL
trays	NULL
for	NULL
5	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

After	NULL
stimulation	NULL
the	NULL
cells	NULL
were	NULL
centrifuged	NULL
,	NULL
supernatant	NULL
removed	NULL
and	NULL
180	NULL
pl	NULL
reaction	NULL
media	NULL
(	NULL
100	NULL
mM	NULL
Na	NULL
,	NULL
HPO	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
10	NULL
mM	NULL
KCI	NULL
,	NULL
1	NULL
mM	NULL
MgSO	NULL
,	NULL
,	NULL
0.1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
0.5	NULL
mM	NULL
4-methylumbellifery	NULL
}	NULL
-G-p-galactoside	NULL
)	NULL
was	NULL
added	NULL
.	NULL

After	NULL
1	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
the	NULL
reaction	NULL
was	NULL
stopped	NULL
by	NULL
adding	NULL
75	NULL
gl	NULL
of	NULL
stop	NULL
buffer	NULL
(	NULL
300	NULL
mM	NULL
glycine	NULL
,	NULL
15	NULL
mM	NULL
EDTA	NULL
,	NULL
pH	NULL
11.3	NULL
)	NULL
and	NULL
the	NULL
fluorescence	NULL
at	NULL
460	NULL
nm	NULL
was	NULL
measured	NULL
using	NULL
355	NULL
nm	NULL
excitation	NULL
with	NULL
a	NULL
Titertek	NULL
Fluoroscan	NULL
IL	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
shift	NULL
assay	NULL
Nuclear	NULL
extracts	NULL
were	NULL
made	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
Durand	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1988	NULL
)	NULL
with	NULL
minor	NULL
modifications	NULL
.	NULL

Fifty	NULL
million	NULL
cells	NULL
per	NULL
experimental	NULL
point	NULL
were	NULL
harvested	NULL
and	NULL
washed	NULL
once	NULL
in	NULL
ice	NULL
cold	NULL
phosphate	NULL
buffered	NULL
saline	NULL
and	NULL
the	NULL
following	NULL
steps	NULL
were	NULL
done	NULL
at	NULL
4°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
pelleted	NULL
and	NULL
washed	NULL
once	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
buffer	NULL
A	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
pH	NULL
7.8	NULL
,	NULL
15	NULL
mM	NULL
KCI	NULL
,	NULL
2	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
1.0	NULL
mM	NULL
PMSF	NULL
)	NULL
and	NULL
once	NULL
in	NULL
1	NULL
ml	NULL
buffer	NULL
B	NULL
(	NULL
buffer	NULL
A	NULL
plus	NULL
0.2	NULL
%	NULL
NP-40	NULL
)	NULL
.	NULL

Pelleted	NULL
nuclei	NULL
were	NULL
resuspended	NULL
in	NULL
324	NULL
ul	NULL
of	NULL
buffer	NULL
C	NULL
(	NULL
50	NULL
mM	NULL
HEPES	NULL
pH	NULL
7.8	NULL
,	NULL
50	NULL
mM	NULL
KCl	NULL
,	NULL
0.1	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
DTT	NULL
,	NULL
1.0	NULL
mM	NULL
PMSF	NULL
,	NULL
10	NULL
%	NULL
v/v	NULL
glycerol	NULL
)	NULL
,	NULL
and	NULL
36	NULL
gl	NULL
3	NULL
M	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
,	NULL
SO	NULL
,	NULL
pH	NULL
7.9	NULL
was	NULL
added	NULL
.	NULL

Following	NULL
gentle	NULL
mixing	NULL
for	NULL
30	NULL
min	NULL
,	NULL
the	NULL
viscous	NULL
solution	NULL
was	NULL
centrifuged	NULL
at	NULL
100	NULL
000	NULL
r.p.m	NULL
.	NULL

for	NULL
10	NULL
min	NULL
in	NULL
a	NULL
Beckman	NULL
TLC	NULL
100	NULL
rotor	NULL
.	NULL

An	NULL
equal	NULL
volume	NULL
of	NULL
3	NULL
M	NULL
(	NULL
NH	NULL
,	NULL
)	NULL
;	NULL
,	NULL
SO	NULL
,	NULL
was	NULL
added	NULL
to	NULL
the	NULL
supernatant	NULL
and	NULL
precipitated	NULL
proteins	NULL
were	NULL
pelleted	NULL
at	NULL
50	NULL
000	NULL
r.p.m	NULL
.	NULL

for	NULL
10	NULL
min	NULL
and	NULL
resuspended	NULL
in	NULL
50-100	NULL
gl	NULL
of	NULL
buffer	NULL
C.	NULL
Protein	NULL
samples	NULL
were	NULL
desalted	NULL
by	NULL
'	NULL
passage	NULL
over	NULL
a	NULL
P6DG	NULL
column	NULL
(	NULL
Bio-Rad	NULL
)	NULL
.	NULL

Concentrations	NULL
of	NULL
proteins	NULL
were	NULL
determined	NULL
by	NULL
the	NULL
Bradford	NULL
assay	NULL
(	NULL
Bradford	NULL
,	NULL
1976	NULL
)	NULL
.	NULL

Electrophoretic	NULL
mobility	NULL
assays	NULL
were	NULL
done	NULL
essentially	NULL
as	NULL
described	NULL
(	NULL
Fried	NULL
and	NULL
Crothers	NULL
,	NULL
1981	NULL
;	NULL
Garner	NULL
and	NULL
Revzin	NULL
,	NULL
1981	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
for	NULL
NFAT	NULL
and	NULL
NFxB	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
20	NULL
4l	NULL
in	NULL
a	NULL
solution	NULL
consisting	NULL
of	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
10	NULL
mM	NULL
Tris-HCl	NULL
pH	NULL
7.5	NULL
,	NULL
0.5	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
and	NULL
1.7	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
.	NULL

Binding	NULL
reactions	NULL
for	NULL
NFIL2B	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
50	NULL
mM	NULL
NaCl	NULL
,	NULL
25	NULL
mM	NULL
Tris	NULL
borate	NULL
pH	NULL
7.5	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
and	NULL
1.7	NULL
ug	NULL
poly	NULL
(	NULL
dI-dC	NULL
)	NULL
and	NULL
binding	NULL
reactions	NULL
for	NULL
AP-1	NULL
were	NULL
carried	NULL
out	NULL
in	NULL
a	NULL
solution	NULL
consisting	NULL
of	NULL
50	NULL
mM-HCI	NULL
pH	NULL
7.5	NULL
,	NULL
13	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
1	NULL
mM	NULL
EDTA	NULL
,	NULL
5	NULL
%	NULL
glycerol	NULL
and	NULL
1.7	NULL
ug	NULL
poly	NULL
dl-dC	NULL
.	NULL

Five	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
used	NULL
for	NULL
each	NULL
experimental	NULL
point	NULL
except	NULL
for	NULL
NF-AT	NULL
binding	NULL
reactions	NULL
in	NULL
which	NULL
10	NULL
ug	NULL
of	NULL
protein	NULL
was	NULL
used	NULL
.	NULL

The	NULL
protein	NULL
solutions	NULL
were	NULL
incubated	NULL
for	NULL
60	NULL
min	NULL
on	NULL
ice	NULL
with	NULL
0.1	NULL
-0.5	NULL
ng	NULL
of	NULL
end-labeled	NULL
double	NULL
stranded	NULL
oligonucleotides	NULL
.	NULL

The	NULL
probe	NULL
for	NULL
NF-AT	NULL
was	NULL
derived	NULL
by	NULL
annealing	NULL
oligonucleotides	NULL
gatcTAAGGAG-GAAAAACTGTTTCATG	NULL
and	NULL
gatcCATGAAACAGTTTTTCCTCCTTA	NULL
.	NULL

The	NULL
probe	NULL
for	NULL
AP-1	NULL
was	NULL
derived	NULL
by	NULL
annealing	NULL
oligonucleotides	NULL
tegaGTGACTCAGCGCG	NULL
and	NULL
tegaCGCGCTGAGTCAC	NULL
which	NULL
represents	NULL
the	NULL
sequence	NULL
of	NULL
the	NULL
AP-1	NULL
binding	NULL
site	NULL
from	NULL
the	NULL
human	NULL
metallothionein	NULL
enhancer	NULL
(	NULL
Lee	NULL
et	NULL
al	NULL
.	NULL

,	NULL
1987	NULL
)	NULL
.	NULL

The	NULL
probes	NULL
for	NULL
NFIL2B	NULL
and	NULL
NFxB	NULL
were	NULL
derived	NULL
from	NULL
the	NULL
oligonucleotides	NULL
that	NULL
were	NULL
used	NULL
for	NULL
the	NULL
construction	NULL
of	NULL
NFIL2ZH	NULL
and	NULL
KBZH	NULL
.	NULL

Radioactive	NULL
nucleotides	NULL
were	NULL
filled	NULL
in	NULL
to	NULL
the	NULL
annealed	NULL
oligonucleotides	NULL
by	NULL
Klenow	NULL
enzyme	NULL
.	NULL

The	NULL
samples	NULL
were	NULL
electrophoresed	NULL
at	NULL
4432	NULL
room	NULL
temperature	NULL
in	NULL
4.5	NULL
%	NULL
polyacrylamide	NULL
gels	NULL
in	NULL
90	NULL
mM	NULL
Tris-borate	NULL
,	NULL
90	NULL
mM	NULL
boric	NULL
acid	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
except	NULL
the	NULL
samples	NULL
for	NULL
NFIL2B	NULL
and	NULL
AP-1	NULL
which	NULL
were	NULL
electrophoresed	NULL
in	NULL
the	NULL
above	NULL
buffer	NULL
diluted	NULL
4-fold	NULL
.	NULL

Acknowledgements	NULL
These	NULL
studies	NULL
were	NULL
supported	NULL
by	NULL
grants	NULL
#	NULL
HL	NULL
33942	NULL
and	NULL
CA39612	NULL
to	NULL
G.R.C	NULL
.	NULL

and	NULL
the	NULL
Howard	NULL
Hughes	NULL
Medical	NULL
Institute	NULL
,	NULL
by	NULL
a	NULL
grant	NULL
CA42509	NULL
to	NULL
L.A.H	NULL
.	NULL

and	NULL
by	NULL
a	NULL
grant	NULL
from	NULL
Paolo	NULL
Foundation	NULL
to	NULL
P.S.M	NULL
.	NULL

References	NULL
Arai	NULL
,	NULL
N.	NULL
,	NULL
Nomura	NULL
,	NULL
D.	NULL
,	NULL
Villaret	NULL
,	NULL
D.	NULL
,	NULL
DeWaal	NULL
Malefijt	NULL
,	NULL
R.	NULL
,	NULL
Seiki	NULL
,	NULL
M.	NULL
,	NULL
Yoshida	NULL
,	NULL
M.	NULL
,	NULL
Minoshima	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Fukuyama	NULL
,	NULL
R.	NULL
,	NULL
Maekawa	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Kudoh	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
142	NULL
,	NULL
274-282	NULL
.	NULL

Bauerle	NULL
,	NULL
P.A	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
,	NULL
53	NULL
,	NULL
211-217	NULL
.	NULL

Bickel	NULL
,	NULL
M.	NULL
,	NULL
Tsuda	NULL
,	NULL
H.	NULL
,	NULL
Amstad	NULL
,	NULL
P.	NULL
,	NULL
Evequoz	NULL
,	NULL
V.	NULL
,	NULL
Mergenhagen	NULL
,	NULL
$	NULL
.E	NULL
.	NULL

and	NULL
Wahl	NULL
,	NULL
S.M	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
84	NULL
,	NULL
3274-3277	NULL
.	NULL

Bierer	NULL
,	NULL
B.E	NULL
.	NULL

,	NULL
Mattila	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Standaert	NULL
,	NULL
R.F	NULL
.	NULL

,	NULL
Herzenberg	NULL
,	NULL
.	NULL

A.	NULL
,	NULL
Burakoff	NULL
,	NULL
$	NULL
.J	NULL
.	NULL

,	NULL
Crabtree	NULL
,	NULL
G	NULL
.	NULL

and	NULL
Schreiber	NULL
,	NULL
$	NULL
.L	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
4	NULL
,	NULL
1823-1834	NULL
.	NULL

Bradford	NULL
,	NULL
M.M	NULL
.	NULL

(	NULL
1976	NULL
)	NULL
Anal	NULL
.	NULL

Biochem	NULL
.	NULL

,	NULL
72	NULL
,	NULL
248-254	NULL
.	NULL

Brandl	NULL
,	NULL
C.J	NULL
.	NULL

and	NULL
Deber	NULL
,	NULL
C.M	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
917-921	NULL
.	NULL

Brown	NULL
,	NULL
R.D	NULL
.	NULL

,	NULL
Brewer	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Koenig	NULL
,	NULL
(	NULL
1977	NULL
)	NULL
Biochemistry	NULL
,	NULL
16	NULL
,	NULL
3883-3896	NULL
.	NULL

Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
243	NULL
,	NULL
355-361	NULL
.	NULL

Dumont	NULL
,	NULL
F.J.	NULL
,	NULL
Melino	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
Staruch	NULL
,	NULL
M.J.	NULL
,	NULL
Koprak	NULL
,	NULL
S.L	NULL
.	NULL

,	NULL
Fischer	NULL
,	NULL
R.A	NULL
.	NULL

and	NULL
Sigal	NULL
,	NULL
(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
144	NULL
,	NULL
1418-1428	NULL
.	NULL

Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Shaw	NULL
,	NULL
J.P.	NULL
,	NULL
Bush	NULL
,	NULL
Replogle	NULL
,	NULL
R.E	NULL
.	NULL

,	NULL
Belagaje	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
8	NULL
,	NULL
1715-1724	NULL
.	NULL

Elliot	NULL
,	NULL
J.F	NULL
.	NULL

,	NULL
Lin	NULL
,	NULL
Y.	NULL
,	NULL
Mizel,8.B	NULL
.	NULL

,	NULL
Bleackley	NULL
,	NULL
R.C	NULL
.	NULL

,	NULL
Hamish	NULL
,	NULL
D.G	NULL
.	NULL

and	NULL
Paetkau	NULL
,	NULL
V	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Science	NULL
,	NULL
226	NULL
,	NULL
1439-1441	NULL
.	NULL

Emmel	NULL
,	NULL
E.A	NULL
.	NULL

,	NULL
Verweij	NULL
,	NULL
C.L	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Higgins	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Lacy	NULL
,	NULL
E	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
(	NULL
1989	NULL
)	NULL
Science	NULL
,	NULL
246	NULL
,	NULL
1617-1620	NULL
.	NULL

Fiering	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Northrop	NULL
,	NULL
J.	NULL
,	NULL
Nolan	NULL
,	NULL
G.P	NULL
.	NULL

,	NULL
Mattila	NULL
,	NULL
P.S	NULL
.	NULL

,	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

and	NULL
Herzenberg	NULL
,	NULL
L.A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

,	NULL
4	NULL
,	NULL
1823-1834	NULL
.	NULL

Fisher	NULL
,	NULL
G.	NULL
,	NULL
Wittman-Liebold	NULL
,	NULL
B.	NULL
,	NULL
Lang.K	NULL
.	NULL

,	NULL
Kiefhaber	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Schmid	NULL
,	NULL
F.X	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
337	NULL
,	NULL
476-478	NULL
.	NULL

Fried	NULL
,	NULL
M.	NULL
and	NULL
Crothers	NULL
,	NULL
D.M	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
9	NULL
,	NULL
6505-6525	NULL
.	NULL

Garner	NULL
,	NULL
M.M	NULL
.	NULL

and	NULL
Revzin	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
9	NULL
,	NULL
3047-3060	NULL
.	NULL

Greenberg	NULL
.	NULL

M.E	NULL
.	NULL

,	NULL
Hermanowski	NULL
,	NULL
A.L	NULL
.	NULL

and	NULL
Ziff	NULL
,	NULL
E.B	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
6	NULL
,	NULL
1050-1057	NULL
.	NULL

Haendler	NULL
,	NULL
B.	NULL
,	NULL
Hofer-Warbinek	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Hofer	NULL
,	NULL
E	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
6	NULL
,	NULL
947-950	NULL
.	NULL

Halazonetis	NULL
,	NULL
T.D	NULL
.	NULL

,	NULL
Georgopoulos.K	NULL
.	NULL

,	NULL
Greenberg	NULL
,	NULL
M.E	NULL
.	NULL

and	NULL
Leder	NULL
,	NULL
P	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Cell	NULL
,	NULL
55	NULL
,	NULL
917-924	NULL
.	NULL

Handschumacher	NULL
,	NULL
R.E	NULL
.	NULL

,	NULL
Harding	NULL
,	NULL
M.W	NULL
.	NULL

,	NULL
Rice	NULL
,	NULL
J.	NULL
,	NULL
Drugge	NULL
,	NULL
R.J	NULL
.	NULL

and	NULL
Speicher	NULL
,	NULL
D	NULL
.	NULL

W.	NULL
(	NULL
1984	NULL
)	NULL
Science	NULL
,	NULL
226	NULL
,	NULL
544-547	NULL
.	NULL

Harding	NULL
.	NULL

M.W	NULL
.	NULL

,	NULL
Galat	NULL
,	NULL
A.	NULL
,	NULL
Uehling	NULL
,	NULL
D.E	NULL
.	NULL

and	NULL
Schreiber	NULL
,	NULL
S.L	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
341	NULL
,	NULL
758-760	NULL
.	NULL

Lang	NULL
,	NULL
K.	NULL
,	NULL
Schmid	NULL
,	NULL
F.X	NULL
.	NULL

and	NULL
Fischer	NULL
,	NULL
G	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Nature	NULL
,	NULL
329	NULL
,	NULL
268-270	NULL
.	NULL

Lee	NULL
,	NULL
W.	NULL
,	NULL
Mitchell	NULL
,	NULL
P	NULL
.	NULL

and	NULL
Tjian	NULL
,	NULL
R	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
Cell	NULL
,	NULL
49	NULL
,	NULL
741-752	NULL
.	NULL

Leung	NULL
.	NULL

,	NULL
K	NULL
.	NULL

and	NULL
Nabel	NULL
,	NULL
G.J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Nature	NULL
,	NULL
333	NULL
,	NULL
776-778	NULL
.	NULL

Lin	NULL
,	NULL
L.N	NULL
.	NULL

,	NULL
Hasumi	NULL
,	NULL
H	NULL
.	NULL

and	NULL
Brandts	NULL
,	NULL
J.F	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
,	NULL
956	NULL
,	NULL
256-266	NULL
.	NULL

Maki	NULL
,	NULL
N.	NULL
,	NULL
Sekiguchi	NULL
,	NULL
F.	NULL
,	NULL
Nishimaki	NULL
,	NULL
J.	NULL
,	NULL
Miwa	NULL
,	NULL
K.	NULL
,	NULL
Hayano	NULL
,	NULL
T	NULL
.	NULL

,	NULL
Takahashi	NULL
,	NULL
N	NULL
.	NULL

and	NULL
Suzuki	NULL
,	NULL
M.	NULL
(	NULL
1990	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
87	NULL
,	NULL
5440-5443	NULL
.	NULL

Marsh	NULL
,	NULL
H.C.	NULL
,	NULL
Scott	NULL
,	NULL
M.E	NULL
.	NULL

,	NULL
Hiskey	NULL
,	NULL
R.G	NULL
.	NULL

and	NULL
Koehler	NULL
,	NULL
K.A	NULL
.	NULL

(	NULL
1979	NULL
)	NULL
Biochem	NULL
.	NULL

J.	NULL
,	NULL
183	NULL
,	NULL
513-517	NULL
.	NULL

Melton	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Krieg	NULL
,	NULL
P.A	NULL
.	NULL

,	NULL
Rebagliati	NULL
,	NULL
M.R	NULL
.	NULL

,	NULL
Maniatis	NULL
,	NULL
T.	NULL
,	NULL
Zinn	NULL
,	NULL
K	NULL
.	NULL

and	NULL
Green	NULL
,	NULL
M.R	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Nucleic	NULL
Acids	NULL
Res	NULL
.	NULL

,	NULL
12	NULL
,	NULL
7035-7056	NULL
.	NULL

Mustelin	NULL
,	NULL
T.	NULL
,	NULL
Coggeshall	NULL
,	NULL
K.M	NULL
.	NULL

,	NULL
Isakov	NULL
,	NULL
N	NULL
.	NULL

and	NULL
Altman	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Science	NULL
,	NULL
247	NULL
,	NULL
1584-1587	NULL
.	NULL

Nishizuka	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Nature	NULL
,	NULL
334	NULL
,	NULL
661-665	NULL
.	NULL

Nolan	NULL
,	NULL
G.P	NULL
.	NULL

,	NULL
Fiering	NULL
,	NULL
S.	NULL
,	NULL
Nicolas	NULL
,	NULL
J.F	NULL
.	NULL

and	NULL
Herzenberg	NULL
,	NULL
L.A.	NULL
(	NULL
1988	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
85	NULL
,	NULL
2603-2607	NULL
.	NULL

Reed	NULL
,	NULL
J.C.	NULL
,	NULL
Alpers	NULL
,	NULL
J.D	NULL
.	NULL

,	NULL
Nowell	NULL
,	NULL
P.C	NULL
.	NULL

and	NULL
Hoover	NULL
,	NULL
R.G	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
83	NULL
,	NULL
3982-3986	NULL
.	NULL

Sawada	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Suzuki	NULL
,	NULL
G.	NULL
,	NULL
Kawase	NULL
,	NULL
Y.	NULL
and	NULL
Takaku	NULL
,	NULL
F	NULL
.	NULL

(	NULL
1987	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
139	NULL
,	NULL
1797-1803	NULL
.	NULL

Schmidt	NULL
,	NULL
A.	NULL
,	NULL
Hennighausen	NULL
,	NULL
L	NULL
.	NULL

and	NULL
Siebenlist	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
64	NULL
,	NULL
4037-4041	NULL
.	NULL

Schneuwly	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Shortridge	NULL
,	NULL
R.D	NULL
.	NULL

,	NULL
Larrivee	NULL
,	NULL
D.C.	NULL
,	NULL
Ono	NULL
,	NULL
T.	NULL
,	NULL
Ozaki	NULL
,	NULL
M	NULL
.	NULL

and	NULL
Pak	NULL
,	NULL
W.L	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
86	NULL
,	NULL
5390-5394	NULL
.	NULL

Sen	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Baltimore	NULL
,	NULL
D	NULL
.	NULL

(	NULL
1986	NULL
)	NULL
Cell	NULL
,	NULL
47	NULL
,	NULL
921-928	NULL
.	NULL

Serfling	NULL
,	NULL
E.	NULL
,	NULL
Barthelmis	NULL
,	NULL
R.	NULL
,	NULL
Pfeuffer	NULL
,	NULL
I.	NULL
,	NULL
Schenk	NULL
,	NULL
B.	NULL
,	NULL
Zarius	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Swoboda	NULL
,	NULL
R.	NULL
,	NULL
Mercurio	NULL
,	NULL
F	NULL
.	NULL

and	NULL
Karin	NULL
,	NULL
M	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
EMBO	NULL
J.	NULL
,	NULL
8	NULL
,	NULL
465-473	NULL
.	NULL

Shapira	NULL
,	NULL
S.K	NULL
.	NULL

,	NULL
Chou	NULL
,	NULL
J.	NULL
,	NULL
Richaud	NULL
,	NULL
F.V	NULL
.	NULL

and	NULL
Casadaban	NULL
,	NULL
M.J	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Gene	NULL
,	NULL
25	NULL
,	NULL
71-82	NULL
.	NULL

Shaw	NULL
,	NULL
J.P	NULL
.	NULL

Utz	NULL
,	NULL
P.J	NULL
.	NULL

,	NULL
Durand	NULL
,	NULL
D.B	NULL
.	NULL

,	NULL
Toole	NULL
,	NULL
J.J..	NULL
Emmel	NULL
,	NULL
E.A	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Science	NULL
,	NULL
241	NULL
,	NULL
202-205	NULL
.	NULL

Shieh	NULL
,	NULL
B.H	NULL
.	NULL

,	NULL
Stamnes	NULL
,	NULL
M.A	NULL
.	NULL

,	NULL
Seavello	NULL
,	NULL
S.	NULL
,	NULL
Harris	NULL
,	NULL
G.L	NULL
.	NULL

and	NULL
Zuker	NULL
,	NULL
C.S	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
338	NULL
,	NULL
67-70	NULL
.	NULL

Siekierka	NULL
,	NULL
J.J.	NULL
,	NULL
Hung	NULL
,	NULL
$	NULL
.H.Y	NULL
.	NULL

,	NULL
Poe	NULL
,	NULL
M.	NULL
,	NULL
Lin	NULL
,	NULL
C.S	NULL
.	NULL

and	NULL
Sigal	NULL
,	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
341	NULL
,	NULL
755-757	NULL
.	NULL

Standaert	NULL
,	NULL
R.F	NULL
.	NULL

,	NULL
Galat	NULL
,	NULL
A.	NULL
,	NULL
Verdine	NULL
,	NULL
G.L	NULL
.	NULL

and	NULL
Schreiber	NULL
,	NULL
$	NULL
.L	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
Nature	NULL
,	NULL
346	NULL
,	NULL
671-674	NULL
.	NULL

Sugden	NULL
,	NULL
B.	NULL
,	NULL
Marsh	NULL
,	NULL
K	NULL
.	NULL

and	NULL
Yates	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

,	NULL
5	NULL
,	NULL
410-413	NULL
.	NULL

Takahashi	NULL
,	NULL
N.	NULL
,	NULL
Hayano	NULL
,	NULL
T	NULL
.	NULL

and	NULL
Suzuki	NULL
,	NULL
M.	NULL
(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
337	NULL
,	NULL
473-475	NULL
.	NULL

Tocci	NULL
,	NULL
M.J.	NULL
,	NULL
Matkovich	NULL
,	NULL
D.A	NULL
.	NULL

,	NULL
Collier.K	NULL
.	NULL

A.	NULL
,	NULL
Kwok	NULL
,	NULL
P.	NULL
,	NULL
Dumont	NULL
,	NULL
F.	NULL
,	NULL
Lin	NULL
,	NULL
$	NULL
.	NULL

,	NULL
Degudicibus	NULL
,	NULL
S.	NULL
,	NULL
Sickierka	NULL
,	NULL
J.J.	NULL
,	NULL
Chin	NULL
,	NULL
J	NULL
.	NULL

and	NULL
Hutchinson	NULL
,	NULL
N.I	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
143	NULL
,	NULL
718-726	NULL
.	NULL

Tropschug	NULL
,	NULL
M.	NULL
,	NULL
Barthelmess,1.B	NULL
.	NULL

and	NULL
Neupert	NULL
,	NULL
W	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Nature	NULL
,	NULL
342	NULL
,	NULL
953-955.	NULL
van	NULL
Doren	NULL
,	NULL
K.	NULL
,	NULL
Hanahan	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Gluzman	NULL
,	NULL
Y	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
J	NULL
.	NULL

Virol	NULL
.	NULL

,	NULL
50	NULL
,	NULL
606-614	NULL
.	NULL

Verwejj	NULL
,	NULL
C.	NULL
,	NULL
Guidos	NULL
,	NULL
C	NULL
.	NULL

and	NULL
Crabtree	NULL
,	NULL
G.R	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

,	NULL
in	NULL
press	NULL
.	NULL

Weiss	NULL
,	NULL
A.J.I	NULL
.	NULL

,	NULL
Shoback	NULL
,	NULL
D	NULL
.	NULL

and	NULL
Stobo	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
,	NULL
81	NULL
,	NULL
4169-4173	NULL
.	NULL

Wiskocil	NULL
,	NULL
R.	NULL
,	NULL
Weiss	NULL
,	NULL
A.	NULL
,	NULL
Imboden	NULL
,	NULL
J.	NULL
,	NULL
Kamin-Lewis	NULL
,	NULL
R	NULL
.	NULL

and	NULL
Stobo	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1985	NULL
)	NULL
J	NULL
.	NULL

Immunol	NULL
.	NULL

,	NULL
134	NULL
,	NULL
1599-1603	NULL
.	NULL

Received	NULL
on	NULL
August	NULL
14	NULL
,	NULL
1990	NULL
;	NULL
revised	NULL
on	NULL
September	NULL
20	NULL
,	NULL
1990	NULL
Signal	NULL
transduction	NULL
in	NULL
T	NULL
lymphocyte	NULL
activation	NULL
4433	NULL

